Biotelemetry 10-K 23 Feb 15 2014 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Dec. 31, 2014	Feb. 18, 2015	Jun. 30, 2014
Document and Entity Information
Entity Registrant Name	BioTelemetry, Inc.
Entity Central Index Key	1574774
Document Type	10-K
Document Period End Date	31-Dec-14
Amendment Flag	FALSE
Current Fiscal Year End Date	-19
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Accelerated Filer
Entity Public Float			$163,218,174
Entity Common Stock, Shares Outstanding		26,734,569
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	FY

CONSOLIDATED_BALANCE_SHEETS

CONSOLIDATED BALANCE SHEETS (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Current assets:
Cash and cash equivalents	$20,007	$22,151
Accounts receivable, net of allowance for doubtful accounts of $10,347 and $7,555 at December 31, 2014 and 2013, respectively	15,184	11,437
Other accounts receivable, net of allowance for doubtful accounts of $315 and $85 at December 31, 2014 and 2013, respectively	9,362	5,680
Inventory	2,566	2,554
Prepaid expenses and other current assets	2,352	2,433
Total current assets	49,471	44,255
Property and equipment, net	21,703	18,779
Intangible assets, net	22,720	7,312
Goodwill	29,596	16,469
Other assets	1,288	731
Total assets	124,778	87,546
Current liabilities:
Accounts payable	13,195	8,718
Accrued liabilities	18,460	8,190
Current portion of capital leases	480	187
Current portion of long term debt	938
Deferred revenue	2,248	1,945
Total current liabilities	35,321	19,040
Deferred tax liability	1,258	767
Long term portion of capital leases	388	469
Long term debt	23,070
Deferred rent	1,065	441
Total liabilities	61,102	20,717
Shareholders' equity:
Common stock-$.001 par value as of December 31, 2014 and 2013; 200,000,000 shares authorized as of December 31, 2014 and 2013; 26,693,248 and 25,812,754 shares issued and outstanding at December 31, 2014 and 2013, respectively	27	26
Paid-in capital	267,236	260,597
Accumulated deficit	-203,587	-193,794
Total shareholders' equity	63,676	66,829
Total liabilities and shareholders' equity	$124,778	$87,546

CONSOLIDATED_BALANCE_SHEETS_Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, except Share data, unless otherwise specified
CONSOLIDATED BALANCE SHEETS
Accounts receivable-patient services, allowance for doubtful accounts (in dollars)	$10,347	$7,555
Other accounts receivable, allowance for doubtful accounts (in dollars)	$315	$85
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	26,693,248	25,812,754
Common stock, shares outstanding	26,693,248	25,812,754

CONSOLIDATED_STATEMENTS_OF_OPE

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Revenues:
Patient services	$133,178	$100,386	$93,640
Research services	19,744	20,329	8,333
Product	13,656	8,786	9,521
Total revenues	166,578	129,501	111,494
Cost of revenues:
Patient services	54,942	34,179	36,793
Research services	10,646	11,317	3,726
Product	7,526	4,935	5,074
Total cost of revenues	73,114	50,431	45,593
Gross profit	93,464	79,070	65,901
Operating expenses:
General and administrative	45,131	36,569	32,644
Sales and marketing	28,805	26,275	25,604
Bad debt expense	9,347	7,787	11,912
Research and development	7,396	7,338	4,664
Integration, restructuring and other charges	7,098	7,982	4,236
Total operating expenses	97,777	85,951	79,060
Loss from operations	-4,313	-6,881	-13,159
Other (loss) income (net)	-7,793	-223	52
Loss before income taxes	-12,106	-7,104	-13,107
Benefit (provision) from income taxes	2,313	-215	905
Net loss	-9,793	-7,319	-12,202
Net loss per common share:
Basic and diluted (in dollars per share)	($0.37)	($0.29)	($0.49)
Weighted average number of common shares outstanding:
Basic and diluted (in shares)	26,444,626	25,543,646	24,933,656
Unrealized gains/(losses) on securities:
Unrealized holding gains/(losses) arising during the period			16
Comprehensive loss	($9,793)	($7,319)	($12,186)

CONSOLIDATED_STATEMENTS_OF_CAS

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Operating activities
Net loss	($9,793)	($7,319)	($12,202)
Adjustments to reconcile net loss to net cash provided by operating activities:
Provision for doubtful accounts	9,347	7,787	11,912
Depreciation	8,858	9,978	8,037
Increase (decrease) in deferred rent	355	-215	-198
Deferred income tax (benefit) expense	-2,499	53	-1,033
Stock-based compensation	4,037	3,303	3,747
Amortization of intangibles	3,692	2,340	1,341
Loss on extinguishment of debt	203
Amortization of investment premium			268
Changes in operating assets and liabilities:
Accounts receivable	-12,795	-4,597	-3,635
Inventory	299	340	-885
Prepaid expenses and other assets	-128	-637	691
Accounts payable	47	2,369	552
Accrued and other liabilities	7,188	-2,143	-2,852
Net cash provided by operating activities	8,811	11,259	5,743
Investing activities
Acquisition of businesses, net of cash acquired	-14,100		-28,155
Purchases of property and equipment and investment in internally developed software	-12,781	-8,169	-5,962
Purchases of short-term available-for-sale investments			-11,935
Sale or maturity of short-term available-for-sale investments			39,636
Net cash used in investing activities	-26,881	-8,169	-6,416
Financing activities
Proceeds from the exercise of employee stock options and employee stock purchase plan contributions	1,051	847	440
Issuance of long-term debt	41,838
Repayment of long-term debt	-26,434
Principal payments on capital lease obligations	-529	-84
Net cash provided by financing activities	15,926	763	440
Net (decrease) increase in cash and cash equivalents	-2,144	3,853	-233
Cash and cash equivalents - beginning of period	22,151	18,298	18,531
Cash and cash equivalents - end of period	20,007	22,151	18,298
Supplemental disclosure of cash flow information
Cash paid for interest	856	132	295
Cash paid for taxes	148	112	135
Capital lease obligations		$737

CONSOLIDATED_STATEMENTS_OF_SHA

CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (USD $)	Common Stock	Paid-in Capital	Accumulated Other Comprehensive Income	Accumulated Deficit	Total
In Thousands, except Share data, unless otherwise specified
Balance at Dec. 31, 2011	$25	$252,261	($16)	($174,273)	$77,997
Balance (in shares) at Dec. 31, 2011	24,534,601
Increase (Decrease) in Shareholders' Equity
Exercise of stock options and purchase of shares related to the employee stock purchase plan		440			440
Exercise of stock options and purchase of shares related to the employee stock purchase plan (in shares)	194,878
Stock based compensation		3,747			3,747
Stock based compensation (in shares)	459,861
Net loss				-12,202	-12,202
Changes in unrealized gain on available-for-sale investments			16		16
Balance at Dec. 31, 2012	25	256,448		-186,475	69,998
Balance (in shares) at Dec. 31, 2012	25,189,340
Increase (Decrease) in Shareholders' Equity
Exercise of stock options and purchase of shares related to the employee stock purchase plan	1	846			847
Exercise of stock options and purchase of shares related to the employee stock purchase plan (in shares)	348,681
Stock based compensation		3,303			3,303
Stock based compensation (in shares)	274,733
Net loss				-7,319	-7,319
Balance at Dec. 31, 2013	26	260,597		-193,794	66,829
Balance (in shares) at Dec. 31, 2013	25,812,754
Increase (Decrease) in Shareholders' Equity
Exercise of stock options and purchase of shares related to the employee stock purchase plan	1	1,050			1,051
Exercise of stock options and purchase of shares related to the employee stock purchase plan (in shares)	503,036
Stock based compensation		4,037			4,037
Stock based compensation (in shares)	195,437
Issuance of stock related to business combinations		1,552			1,552
Issuance of stock related to business combinations (in shares)	182,021
Net loss				-9,793	-9,793
Balance at Dec. 31, 2014	$27	$267,236		($203,587)	$63,676
Balance (in shares) at Dec. 31, 2014	26,693,248

Organization_and_Description_o

Organization and Description of Business	12 Months Ended
	Dec. 31, 2014
Organization and Description of Business
Organization and Description of Business	1. Organization and Description of Business
	BioTelemetry, Inc. ("BioTelemetry," "Company", "we," "our" or "us"), a Delaware corporation, was formerly known as CardioNet, Inc. CardioNet, Inc. was reorganized under a holding company structure with the new name BioTelemetry, Inc. effective July 31, 2013. On August 1, 2013, we continued trading on The NASDAQ Global Select under the symbol "BEAT.".
	BioTelemetry, Inc. provides cardiac monitoring services, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. Since we became focused on cardiac monitoring in 1999, we have developed a proprietary integrated patient management platform that incorporates a wireless data transmission network, Food and Drug Administration ("FDA") cleared algorithms and medical devices, and 24-hour monitoring service centers.
	We operate under three reportable segments: (1) Patient Services, (2) Product and (3) Research Services. The Patient Services segment is focused on the diagnosis and monitoring of cardiac arrhythmias, or heart rhythm disorders. We offer cardiologists and electrophysiologists with a full spectrum of solutions which provides them with a single source of cardiac monitoring services. These services range from the differentiated MCT service marketed as Mobile Cardiac Outpatient TelemetryTM ("MCOT™") or External Cardiac Ambulatory Telemetry ("ECAT"),"), to wireless and trans telephonic event, Holter, Pacemaker and International Normalized Ratio ("INR") monitoring. The Product segment focuses on the development, manufacturing, testing and marketing of medical devices to medical companies, clinics and hospitals. The Research Services segment is engaged in central core laboratory services providing cardiac monitoring, imaging, scientific consulting and data management services for drug and medical device trials.
	In June 2014, we completed the acquisition of the assets of RadCore Lab, LLC ("RadCore"), an imaging core lab serving the biopharmaceutical and medical device research market. RadCore is included in the Research Services segment.
	In April 2014, we completed the acquisition of substantially all of the assets of Biomedical Systems Corporation ("BMS") cardiac event monitoring, Holter monitoring and mobile telemetry monitoring services. BMS is primarily included in the Patient Services segment.
	In January 2014, we completed the acquisition of Mednet Healthcare Technologies, Inc., Heartcare Corporation of America, Inc., Universal Medical, Inc., and Universal Medical Laboratory, Inc. (together, the "Mednet entities"). Mednet provides cardiac monitoring services and is an original equipment manufacturer of cardiac monitoring devices. Mednet entities are included in the Patient Services and Product segment.
	In August 2012, we completed the acquisition of Cardiocore Lab, Inc. ("Cardiocore"). Cardiocore is a central core laboratory that provides cardiac monitoring services for drug and medical treatment trials. Cardiocore's primary customers are pharmaceutical companies and contract research organizations. Cardiocore is included in our Research Services segment.
	In February 2012, we completed the acquisition of ECG Scanning & Medical Services, Inc. ("ECG Scanning"). Similar to our core Patient Services segment, ECG Scanning was engaged in providing cardiac monitoring services to general practitioners, internal medicine specialists, cardiologists and hospital cardiac care departments. ECG Scanning is included in our Patient Services segment.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2014
Summary of Significant Accounting Policies
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies
	Principles of Consolidation
	The accompanying consolidated financial statements include the accounts of BioTelemetry and its wholly owned subsidiaries. All significant intercompany transactions and balances have been eliminated in consolidation.
	Use of Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires that management make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results may differ from those estimates.
	Fair Value of Financial Instruments
	The fair value of financial instruments is defined as the amount at which the instrument could be exchanged in a current transaction between willing parties. Our financial instruments consist primarily of cash and cash equivalents, accounts receivable, other receivables, accounts payable, short-term and long-term debt. With the exception of the long-term debt, the carrying value of these financial instruments approximates their fair value because of their short-term nature (classified as Level 1). For long-term debt, based on the borrowing rates currently available, the carrying value also approximates fair value as of December 31, 2014 (classified as Level 2). The Company did not have any Level 3 assets or liabilities for the periods ended December 31, 2014 and 2013.
	Cash and Cash Equivalents
	Cash and cash equivalents are held in U.S. financial institutions or in custodial accounts with U.S. financial institutions. Cash equivalents are defined as liquid investments and money market funds with maturity from date of purchase of 90 days or less that are readily convertible into cash and have minimal interest rate risk.
	Accounts Receivable and Allowance for Doubtful Accounts
	Accounts receivable related to the Patient Services segment are recorded at the time revenue is recognized, net of contractual allowances, and are presented on the balance sheet net of allowance for doubtful accounts. The ultimate collection of accounts receivable may not be known for several months after services have been provided and billed. We record allowance for doubtful accounts based on the aging of receivables using historical data. The percentages and amounts used to record bad debt expense and the allowance for doubtful accounts are supported by various methods and analyses, including current and historical cash collections, and the aging of receivables by payor. Because of continuing changes in the health care industry and third party reimbursement, it is possible that our estimates of collectability could change, which could have a material impact on our operations and cash flows.
	Other receivables related to the Product and Research Services segments are recorded at the time revenue is recognized, or when products are shipped or services are performed. We estimate allowance for doubtful accounts on a specific account basis, and consider several factors in our analysis including customer specific information and aging of the account.
	We write off receivables when the likelihood for collection is remote and when we believe collection efforts have been fully exhausted and we do not intend to devote additional resources in attempting to collect. We perform write-offs on a monthly basis. In the Patient Services segment, we wrote off $6,494 and $7,919 of receivables for the years ended December 31, 2014 and 2013, respectively. The impact was a reduction of gross receivables and a reduction in the allowance for doubtful accounts. There were no material write offs in the Product and Research Services segments. Additionally, we recorded bad debt expense of $9,347, $7,787 and $11,912 for the years ended December 31, 2014, 2013, and 2012, respectively. Unfavorable adjustments of $782 and $1,480 were made to accounts receivable in 2014 and 2013, respectively, related to prior years accounts receivable.
	Concentrations of Credit Risk
	Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash, cash equivalents and accounts receivable. We maintain our cash and cash equivalents with high quality financial institutions to mitigate this risk. We perform ongoing credit evaluations of our customers and generally do not require collateral. We record an allowance for doubtful accounts in accordance with the procedures described above. Past-due amounts are written off against the allowance for doubtful accounts when collections are believed to be unlikely and all collection efforts have ceased.
	At December 31, 2014, 2013 and 2012, one customer, Medicare, accounted for 16%, 18% and 20%, respectively, of our net accounts receivable.
	Inventory
	Inventory is valued at the lower of cost (using first-in, first-out cost method) or market (net realizable value or replacement cost). Management periodically reviews inventory for specific future usage, and estimates of impairment of individual inventory items are recorded to reduce inventory to the lower of cost or market.
	Property and Equipment
	Property and equipment is recorded at cost. Depreciation is recorded over the estimated useful life of each class of depreciable assets, and is computed using the straight-line method. Leasehold improvements are amortized over the shorter of the estimated asset life or term of the lease. Repairs and maintenance costs are charged to expense as incurred.
	Impairment of Long-Lived Assets
	We periodically evaluate the recoverability of the carrying value of our long-lived assets based on the criteria established in Accounting Standards Codification (ASC) 360, Property, Plant & Equipment. We consider historical performance and anticipated future results in our evaluation of potential impairment. Accordingly, when indicators of impairment are present, we evaluate the carrying value of these assets in relation to the operating performance of the business and the undiscounted cash flows expected to result from the use of these assets. Impairment losses are recognized when the sum of the expected future cash flows is less than the assets' carrying value.
	Goodwill and Acquired Intangible Assets
	Goodwill is the excess of purchase price of an acquired business over the amounts assigned to assets acquired and liabilities assumed in a business combination. In accordance with ASC 350, Intangibles—Goodwill and Other, goodwill is reviewed for impairment annually, or when events arise that could indicate that impairment exists. The provisions of ASC 350 require that we perform a two-step impairment test. In the first step, we compare the fair value of our reporting units to the carrying value of the reporting units. If the carrying value of the net assets assigned to the reporting units exceeds the fair value of the reporting units, then the second step of the impairment test is performed in order to determine the implied fair value of the reporting units' goodwill. If the carrying value of the reporting units' goodwill exceeds the implied fair value, an impairment loss equal to the difference is recorded.
	For the purpose of performing our goodwill impairment analysis in 2014, we consider our business to be comprised of three reporting units, Patient Services, Product and Research Services. We calculate the fair value of the reporting units utilizing a weighting of the income and market approaches. The income approach is based on a discounted cash flow methodology that includes assumptions for, among other things, forecasted income, cash flow, growth rates, income tax rates, expected tax benefits and long-term discount rates, all of which require significant judgment. The market approach utilizes our market data as well as market data from publicly traded companies that are similar to us. There are inherent uncertainties related to these factors and the judgment applied in the analysis. We believe that the combination of an income and a market approach provides a reasonable basis to estimate the fair value of our reporting units.
	Revenue Recognition
	We recognize approximately 80% of our total revenue from patient monitoring services in our Patient Services segment. We receive a significant portion of our revenue from third party commercial payors and governmental entities. We also receive reimbursement directly from patients through co-pay, deductibles and self-pay arrangements.
	Revenue from the Medicare program is based on reimbursement rates set by CMS. Revenue from contracted commercial payors is recorded at the negotiated contractual rate. Revenue from non-contracted commercial payors is recorded at net realizable value based on historical payment patterns. Adjustments to the estimated net realizable value, based on final settlement with the third party payors, are recorded upon settlement. If we do not have consistent historical information regarding collectability from a given payor, revenue is recognized when cash is received. Unearned amounts are appropriately deferred until service has been completed. For the years ended December 31, 2014, 2013 and 2012, revenue from Medicare as a percentage of total revenue was 32%, 35% and 37%, respectively.
	Revenue received from the sale of products, product repair and supplies is recognized when shipped, or as service is completed.
	Research Services revenue includes revenue for research and core laboratory services. Our Research Services revenues are provided on a fee for service basis, and revenue is recognized as the related services are performed. We also provide consulting services on a time and materials basis and recognize revenues as we perform the services. Our site support revenue, consisting of equipment rentals and sales along with related supplies and logistics management, are recognized at the time of sale or over the rental period. Under a typical contract, customers pay us a portion of our fee for these services upon contract execution as an upfront deposit, some of which is typically nonrefundable upon contract termination. Unearned revenues, including upfront deposits, are deferred, and then recognized as the services are performed.
	For arrangements with multiple deliverables, the revenue is allocated to each element (both delivered and undelivered items) based on their relative selling prices or management's best estimate of their selling prices, when vendor- specific or third-party evidence is unavailable.
	We record reimbursements received for out-of-pocket expenses, including freight, incurred as revenue in the accompanying consolidated statements of operations. Revenue generally is recognized net of any taxes collected from customers and subsequently remitted to government authorities.
	Research and Development Costs
	Research and development costs are charged to expense as incurred.
	Net Loss
	We compute net loss per share in accordance with ASC 260, Earnings Per Share. The following summarizes the potential outstanding common stock as of the end of each period:
		December 31,			December 31,			December 31,
		2014			2013			2012
	Employee stock purchase plan estimated share options outstanding		39,232			81,848			50,903
	Common stock options and restricted stock units ("RSUs") outstanding		4,115,486			3,993,590			3,669,103
	Common stock available for grant		2,262,168			1,761,840			1,442,434
	Common stock		26,693,248			25,812,754			25,189,340
	Total		33,110,134			31,650,032			30,351,780
	Basic net loss per share is computed by dividing net loss by the weighted average number of fully vested common shares outstanding during the period. Diluted net loss per share is computed by giving effect to all potential dilutive common shares, including stock options, and RSUs.
	The following table presents the calculation of historical basic and diluted net loss per share:
		Year Ended December 31,
		2014			2013			2012
		(in thousands, except per share amounts)
	Numerator:
	Net loss	$	(9,793	)	$	(7,319	)	$	(12,202	)
	Denominator:
	Weighted average shares used in computing basic and diluted net loss per share		26,444,626			25,543,646			24,933,656
	Basic and diluted net loss per share	$	(0.37	)	$	(0.29	)	$	(0.49	)
	If the outstanding vested options or RSUs were exercised or converted into common stock, the result would be anti-dilutive for the years ended December 31, 2014, 2013 and 2012. Accordingly, basic and diluted net loss per share are the same for the years ended December 31, 2014, 2013 and 2012.
	Stock-Based Compensation
	ASC 718, Compensation—Stock Compensation, addresses the accounting for share-based payment transactions in which an enterprise receives employee services in exchange for (a) equity instruments of the enterprise or (b) liabilities that are based on the fair value of the enterprise's equity instruments or that may be settled by the issuance of such equity instruments. ASC 718 requires that an entity measures the cost of equity-based service awards based on the grant-date fair value of the award and recognizes the cost of such awards over the period during which the employee is required to provide service in exchange for the award (the vesting period). ASC 718 requires that an entity measures the cost of liability-based service awards based on current fair value that is re-measured subsequently at each reporting date through the settlement date. We account for equity awards issued to non-employees in accordance with ASC 505-50, Equity-Based Payments to Non-Employees.
	Income Taxes
	We account for income taxes under the liability method, as described in ASC 740, Income Taxes. Deferred income taxes are recognized for the tax consequences of temporary differences between the tax and financial statement reporting bases of assets and liabilities. A valuation allowance for net deferred tax assets is provided unless realizability is judged to be more likely than not.
	Segment Information
	ASC 280, Segment Reporting, establishes standards for reporting information regarding operating segments in annual financial statements. Operating segments are identified as components of an enterprise for which separate discrete financial information is available for evaluation by the chief operating decision-maker, or decision-making group in making decisions on how to allocate resources and assess performance.
	We report our business under three segments: Patient Services, Product and Research Services. The Patient Services segment is focused on the monitoring of cardiac arrhythmias or heart rhythm disorders in a healthcare setting. The Product segment focuses on the development, manufacturing, testing and marketing of medical devices to medical companies, clinics and hospitals. The Research Services segment includes our operations that engage in central core laboratory services in a research environment, which includes certain equipment rental and Product sales. In addition, we realigned the Product segment to exclude central core laboratory research operations previously reported in this segment and repositioned these operations into the Research Services segment.
	Recent Accounting Pronouncements
	In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers, which provides guidance for revenue recognition. The new standard will require revenue recognized to represent the transfer of promised goods or services to customers in an amount that reflects the consideration in which we expect to receive in exchange for those goods or services. The standard also requires new, expanded disclosures regarding revenue recognition and is effective for the annual reporting periods beginning after December 15, 2016. We are currently evaluating the impact the adoption of this standard will have on the consolidated financial statements.
	In July 2013, the FASB issued ASU 2013-11, Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists. The new guidance provides specific financial statement presentation requirements of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. The guidance states that an unrecognized tax benefit in those circumstances should be presented as a reduction to the deferred tax asset. The ASU is effective for fiscal years, and interim periods within those years, beginning after December 15, 2013. The amendment did not have a material impact on our results of operations, cash flows, or financial position.

Business_Combinations

Business Combinations	12 Months Ended
	Dec. 31, 2014
Business Combinations
Business Combinations	3. Business Combinations
	RadCore Lab, LLC
	On June 3, 2014, we acquired the assets of RadCore Lab, LLC ("RadCore"), an imaging core lab serving the biopharmaceutical and medical device research market. This acquisition broadens our offerings and adds new oncology, musculoskeletal and neurological imaging capabilities, supported by a state-of-the-art, cloud-based analysis platform. We paid $400 in cash at closing and 22,513 shares of our common stock, valued at $200 at closing. While this acquisition provides growth potential, the acquisition of RadCore did not have a material effect on our financial condition, results of operations or cash flows.
	Biomedical Systems Corporation
	On April 3, 2014, we completed the acquisition of substantially all of the assets of Biomedical Systems Corporation's ("BMS") cardiac event monitoring, Holter monitoring and mobile telemetry monitoring services. The acquisition gave us access to internally developed Holter software and to established customer relationships. We paid $8,000 in cash at closing and 62,859 shares of our common stock, valued at $650 at closing. While the acquisition has been included within the consolidated results of operations and financial condition from the date of the acquisition, BMS did not have a material effect on our results of operations or cash flows.
	The amounts below represent the preliminary fair value estimates as of December 31, 2014 and are subject to subsequent adjustment as additional information is obtained during the measurement period. The primary areas of those preliminary estimates that were not yet finalized related to certain tangible assets and identifiable intangible assets. The Company will complete the accounting for the BMS acquisition within a year of the acquisition date.
	Fair value of assets acquired:
	Property and equipment	$	882
	Goodwill		3,559
	Intangible assets		4,209
	Net assets acquired	$	8,650
	While the purchase price allocation has not been finalized, the estimated allocation of intangible assets is comprised of the following:
		Estimated			Fair Value
		Useful Life
		(Years)
	Customer relationships		15		$	2,100
	Technology		4			1,849
	Covenants not to compete		7			260
	Total intangible assets				$	4,209
	Goodwill recorded in connection with this acquisition is attributable to synergies expected to arise from cost savings opportunities. All of the recorded goodwill is included in the Patient Services segment.
	Mednet Healthcare Technologies, Inc.
	On January 31, 2014, we acquired Mednet Healthcare Technologies, Inc., Heartcare Corporation of America, Inc., Universal Medical, Inc., and Universal Medical Laboratory, Inc. (together, "Mednet"). Mednet provides cardiac monitoring services and is an original equipment manufacturer of cardiac monitoring devices. The acquisition gave us access to established customer relationships. Upon the closing of the transaction, we acquired all of the issued and outstanding capital stock, and Mednet became a wholly-owned subsidiary. We paid $5,500 in cash at closing and 96,649 shares of our common stock, valued at $705 at closing. In addition, as a result of the acquisition, we assumed indebtedness from Mednet in the aggregate amount of $9,720, including interest. The acquisition has been included within the consolidated results of operations and financial condition from the date of the acquisition.
	The amounts below represent the preliminary fair value estimates as of December 31, 2014 and are subject to subsequent adjustment as additional information is obtained during the measurement period. The primary areas of those preliminary estimates that were not yet finalized related to certain tangible assets and liabilities acquired, as well as identifiable intangible assets. The Company expects to complete the accounting for the Mednet acquisition within a year of the acquisition date.
	Fair value of assets acquired:
	Cash and cash equivalents	$	(199	)
	Accounts receivable		3,879
	Inventory		311
	Property and equipment		3,429
	Goodwill		9,354
	Intangible assets		9,220
	Other assets		317
	Total assets acquired		26,311
	Liabilities assumed:
	Accounts payable		4,427
	Accrued expenses		2,932
	Other liabilities		3,027
	Long-term debt, capital leases, note payable and related interest		9,720
	Total liabilities assumed		20,106
	Net assets acquired	$	6,205
	While the purchase price allocation has not been finalized, the estimated allocation of intangible assets is comprised of the following:
		Estimated			Fair Value
		Useful Life
		(Years)
	Customer relationships		13		$	6,500
	Technology		5			1,600
	Covenants not to compete		5			420
	Indefinite-lived trade name					700
	Total intangible assets				$	9,220
	Goodwill recorded in connection with this acquisition is attributable to the assembled workforce and synergies expected to arise from cost savings opportunities. All of the recorded goodwill is included in the Patient Services segment.
	The unaudited pro forma information below presents combined results of operations as if the acquisition had occurred at the beginning of the periods presented instead of January 31, 2014. The pro forma information presented below does not include anticipated synergies or certain other expected benefits of the acquisition and should not be used as a predictive measure of our future results of operations. Mednet contributed $23,355 in revenue for the twelve months ended December 31, 2014.
		December 31,
		2014			2013
	Revenue	$	170,076		$	155,415
	Net Loss	$	(8,014	)	$	(8,604	)
	Net loss per common share:
	Basic and Diluted	$	(0.30	)	$	(0.34	)
	Weighted average number of shares:
	Basic		26,444,626			25,640,295
	Cardiocore Lab, Inc.
	On August 29, 2012, we entered into a definitive merger agreement with Cardiocore Lab, Inc. ("Cardiocore"), a Delaware corporation. Upon the closing of the transaction, Cardiocore became a wholly-owned subsidiary. We paid an aggregate purchase price of $23,500 in cash at closing. The acquisition has been included within the consolidated results of operations and financial condition from the date of the acquisition.
	Cardiocore is engaged in central core laboratory services that provide cardiac monitoring for drug and medical treatment trials. Cardiocore's primary customers are pharmaceutical companies and contract research organizations. The acquisition gave us access to industry expertise, an established operating structure and a substantial footprint in the core laboratory industry.
	The unaudited pro forma information below presents combined results of operations as if the acquisition had occurred at the beginning of the periods presented instead of August 29, 2012. The pro forma information is based on historical results adjusted for the effect of purchase accounting and is not necessarily indicative of the results of operations of the combined entity had the acquisition occurred at the beginning of the periods presented, nor is it necessarily indicative of future results.
		December 31,
		2012
Revenue	$	124,698
Net Income (Loss)	$	(10,936	)
Net Income per common share:
Basic and Diluted	$	(0.47	)
Weighted average number of shares:
Basic		24,933,656
ECG Scanning and Medical Services, Inc.
On February 10, 2012, we entered into and closed on a definitive Stock Purchase Agreement (the "Stock Purchase Agreement") with ECG Scanning and Medical Services, Inc., an Ohio corporation ("ECG Scanning"). Upon the closing of the transaction, we acquired all of the issued and outstanding capital stock, and ECG Scanning became a wholly-owned subsidiary. ECG Scanning was a provider of cardiac monitoring services in the United States. We paid an aggregate cash purchase price of $5,800 at closing and up to an additional $600 in cash, with an estimated fair value of $570, upon the achievement of certain performance targets approximately one year from the date of purchase. At December 31, 2012, the estimated fair value of the earn-out was $0. The reduction of the liability was recognized in the Statement of Operations and Comprehensive Income (Loss) in the Integration, restructuring, and other line. The acquisition has been included within the consolidated results of operations and financial condition from the date of the acquisition. The acquisition gave us access to established customer relationships, and entry into additional regions and geographic locations.

Inventory

Inventory	12 Months Ended
	Dec. 31, 2014
Inventory
Inventory	4. Inventory
	Inventory consists of the following:
		December 31,
		2014		2013
	Raw materials and supplies	$	2,347	$	2,404
	Finished goods		219		150
	Total inventories	$	2,566	$	2,554
	Inventories, which include purchased parts, materials, direct labor and applied manufacturing overhead, are stated at the lower of cost or net realizable value, with cost determined by use of the first-in, first-out method.

Property_and_Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2014
Property and Equipment
Property and Equipment	5. Property and Equipment
	Property and equipment consists of the following:
			December 31,
		Estimated
		Useful Life
		(Years)	2014			2013
	Cardiac monitoring devices, device parts and components	3 - 5	$	47,190		$	37,273
	Computers and purchased software	3 - 5		12,614			13,302
	Equipment, tools and molds	3 - 5		5,543			5,384
	Furniture and fixtures	7		1,396			2,863
	Leasehold improvements	Life of lease		2,930			2,665
	Capital leases	3 - 7		1,884			737
	Total property and equipment, at cost			71,557			62,224
	Less accumulated depreciation			(49,854	)		(43,445	)
	Total property and equipment, net		$	21,703		$	18,779
	Depreciation expense associated with property and equipment was $8,858, $9,978 and $8,037, for the years ended December 31, 2014, 2013 and 2012, respectively.

Goodwill_and_Intangible_Assets

Goodwill and Intangible Assets	12 Months Ended
	Dec. 31, 2014
Goodwill and Intangible Assets
Goodwill and Intangible Assets	6. Goodwill and Intangible Assets
	Goodwill was recognized at the time of our acquisitions. The carrying amount of goodwill as of December 31, 2014 and 2013 was $29,596 and $16,469, respectively.
	The changes in the carrying amounts of goodwill by segment were as follows:
		Reporting Segment
		Patient			Research			Product		Total
		Services			Services
	Balance at December 31, 2013	$	1,577		$	11,735		$	3,157	$	16,469
	Goodwill acquired during the year		12,912			215			—		13,127
	Balance at December 31, 2014	$	14,489		$	11,950		$	3,157	$	29,596
	The gross carrying amounts and accumulated amortization of our intangible assets as of December 31, 2014 and 2013 are as follows:
				December 31,
		Estimated
		Useful Life
		(Years)		2014			2013
	Customer relationships	5 - 15		$	10,700		$	2,100
	Technology including internally developed software	3 - 5			12,649			4,000
	Signed backlog	1 - 4			3,160			2,800
	Unsigned backlog	4			600			600
	Covenants not to compete	5 - 7			1,040			360
	Total intangible assets, gross				28,149			9,860
	Customer relationships accumulated amortization				(1,556	)		(722	)
	Proprietary technology accumulated amortization				(3,855	)		(1,902	)
	Signed backlog accumulated amortization				(1,984	)		(1,400	)
	Unsigned backlog accumulated amortization				(350	)		(200	)
	Covenants not to compete accumulated amortization				(295	)		(124	)
	Total accumulated amortization				(8,040	)		(4,348	)
	Indefinite-lived trade name				2,500			1,800
	In-process internally developed software				111			—
	Total intangible assets, net			$	22,720		$	7,312
	The estimated amortization expense for the next five years is summarized as follows at December 31, 2014:
	2015	$	4,628
	2016		3,531
	2017		2,828
	2018		2,342
	2019		1,768
	Thereafter		5,012
	Total intangibles assets, net	$	20,109
	Amortization expense for the years ended December 31, 2014, 2013 and 2012 was $3,692, $2,340 and $1,341, respectively. The increase in amortization expense is driven by the current year acquisitions.
	At December 31, 2014, 2013 and 2012, we performed our required annual impairment test of goodwill. Based on this impairment test, we determined that none of the reporting unit's goodwill was impaired.

Accrued_Expenses

Accrued Expenses	12 Months Ended
	Dec. 31, 2014
Accrued Expenses
Accrued Expenses	7. Accrued Expenses
	Accrued expenses consisted of the following:
		December 31,
		2014		2013
	Accrued compensation	$	5,296	$	4,932
	Accrued professional fees		8,289		1,922
	Accrued purchases		977		311
	Accrued restructuring costs		689		96
	Other		3,209		929
	Total	$	18,460	$	8,190

Integration_Restructuring_and_

Integration, Restructuring and Other Charges	12 Months Ended
	Dec. 31, 2014
Integration, Restructuring and Other Charges
Integration, Restructuring and Other Charges	8. Integration, Restructuring and Other Charges
	We account for expenses associated with exit or disposal activities in accordance with ASC 420, Exit or Disposal Cost Obligations, and record the expenses in "Integration, restructuring and other charges" in our statement of operations, and record the related accrual in the "Accrued expenses" line of our balance sheet.
	For the years ended December 31, 2014, 2013 and 2012, we incurred expenses related to restructuring, integration and other activities. These expenses were primarily a result of our recent patent litigation, the Civil Investigative Demand, as well as the activities surrounding our acquisitions. A summary of these expenses is as follows:
		Year ended December 31,
		2014		2013		2012
	Legal fees	$	4,691	$	5,516	$	1,780
	Severance and employee related costs		1,738		1,410		1,490
	Professional fees		669		492		778
	Expenses related to facility closure		—		564		—
	Other charges		—		—		188
	Total	$	7,098	$	7,982	$	4,236

Shareholders_Equity

Shareholders' Equity	12 Months Ended
	Dec. 31, 2014
Shareholders' Equity
Shareholders' Equity	9. Shareholders' Equity
	Common Stock
	As of December 31, 2014 and 2013, we were authorized to issue 200,000,000 shares of common stock. As of December 31, 2014 and 2013, we had 26,693,248 and 25,812,754 shares outstanding, respectively.
	Preferred Stock
	We maintain an unregistered blank check preferred stock class. As of December 31, 2014 and 2013, there are no shares authorized and outstanding.
	Stock Based Compensation
	2008 Equity Incentive Plan
	Our 2008 Equity Incentive Plan (the 2008 Option Plan) became effective on March 18, 2008. The Plan permits our Board of Directors to grant incentive stock options to employees and non-qualified stock options, restricted stock, performance stock and other stock-based incentive awards to officers, directors, employees and consultants. On that date, we began granting options to purchase shares of common stock to employees, executives, directors and consultants. Under the terms of the 2008 Option Plan, all available shares in the 2003 Option Plan's share reserve automatically roll into the 2008 Option Plan. Any cancellations or forfeitures of granted options under the 2003 Option Plan also automatically roll into the 2008 Option Plan. Beginning on January 1, 2009, and each year thereafter, the number of options available to be granted under the plan will increase by the lesser of 4% of the total number of common shares outstanding or 1,500,000 shares.
	Options granted under the 2008 Option Plan have exercise prices not less than the fair market value at the date of grant and have an expiration date of no greater than ten years from the date of grant. There is no vesting schedule provided in the 2008 Option Plan, and vesting is determined by the Board of Directors on the date of grant.
	The 2008 Equity Incentive Plan has 1,834,017 shares available for grant as of December 31, 2014.
	Stock option activity is summarized for the years ended December 31, 2014, 2013 and 2012 as follows:
		Number			Weighted
		of Shares			Average
					Exercise Price
	Options outstanding as of December 31, 2011		1,846,911		$	10.11
	Granted		1,387,560		$	2.68
	Cancelled		(326,458	)	$	11.34
	Exercised		(2,252	)	$	1.61
	Options outstanding as of December 31, 2012		2,905,761		$	6.44
	Granted		729,439		$	3.24
	Cancelled		(393,770	)	$	5.93
	Exercised		(105,496	)	$	4.43
	Options outstanding as of December 31, 2013		3,135,934		$	5.83
	Granted		582,012		$	8.45
	Cancelled		(310,303	)	$	6.55
	Exercised		(156,791	)	$	3.37
	Options outstanding as of December 31, 2014		3,250,852		$	6.4
	A summary of total outstanding stock options as of December 31, 2014 is as follows:
		Options Outstanding									Options Exercisable
	Range of Exercise Price	Number			Weighted			Weighted			Number		Weighted		Weighted
		Outstanding			Average			Average			Exercisable		Average		Average
					Remaining			Exercise Price					Remaining		Exercise Price
					Contractual								Contractual
					Life (in years)								Life (in years)
	$0.70 - $7.50		2,478,630			6.80		$	4.08			1,750,230		6.37	$	4.43
	$7.51 - $15.00		473,475			8.86		$	8.94			98,945		7.70	$	8.93
	$15.01 - $22.50		218,347			4.28		$	18.42			218,347		4.28	$	18.42
	$22.51 - $31.18		80,400			3.62		$	30.17			80,400		3.62	$	30.17
	$0.70 - $31.18		3,250,852			6.82		$	6.40			2,147,922		6.11	$	7.02
	The table below summarizes certain additional information with respect to our options:
	(In thousands)	2014			2013			2012
	Aggregate intrinsic value of options outstanding at year-end	$	15,258		$	11,183		$	46
	Aggregate intrinsic value of options exercisable at year-end		9,918			4,382			13
	Aggregate intrinsic value of options exercised during the year		840			422			2
	Total cash received from the exercise of stock options for the year ended December 31, 2014, 2013 and 2012 was $529, $467 and $4, respectively. The tax benefit was fully reserved for through a tax valuation allowance.
	Restricted stock units activity is summarized for the years ended December 31, 2014, 2013 and 2012 as follows:
		Number			Weighted Average
		of Shares			Grant Date Fair
					Value
	Restricted stock outstanding as of December 31, 2011		622,080		$	8.17
	Granted		741,379		$	2.82
	Forfeited		(69,854	)	$	3.45
	Vested		(530,263	)	$	8.03
	Restricted stock outstanding as of December 31, 2012		763,342		$	3.54
	Granted		457,200		$	3.52
	Forfeited		(82,813	)	$	3.07
	Vested		(280,073	)	$	4.82
	Restricted stock outstanding as of December 31, 2013		857,656		$	3.15
	Granted		292,079		$	8.48
	Forfeited		(89,664	)	$	3.3
	Vested		(195,437	)	$	6.27
	Restricted stock outstanding as of December 31, 2014		864,634		$	3.68
	In addition, a summary of total outstanding RSUs as of December 31, 2014 is as follows:
	Range of Grant Price	RSUs
Outstanding
$2.16 - $6.75		632,201
$6.76 - $9.75		232,433
$2.16 - $9.75		864,634
We estimate the fair value of our share-based awards to employees and directors using the Black-Scholes option valuation model. The Black-Scholes option valuation model requires the use of certain subjective assumptions. The most significant of these assumptions are the estimates of the expected volatility of the market price of our stock and the expected term of the award. We base our estimates of expected volatility on the historical average of our stock price. The expected term represents the period of time that stock-based awards granted are expected to be outstanding. Other assumptions used in the Black-Scholes option valuation model include the risk-free interest rate and expected dividend yield. The risk-free interest rate for periods pertaining to the contractual life of each option is based on the U.S. Treasury yield of a similar duration in effect at the time of grant. We have never paid, and do not expect to pay, dividends in the foreseeable future.
The fair value of our stock-based awards was estimated at the date of grant using the following weighted average assumptions:
	Year Ended
	December 31,
	2014			2013			2012
Expected volatility		62.8	%		60.3	%		63.4	%
Expected term (in years)		6.49			6.71			6.31
Weighted average risk-free interest rate		1.85	%		1.34	%		1.15	%
Expected dividends		0.0	%		0.0	%		0.0	%
Weighted average grant date fair value per option	$	5.00		$	1.90		$	1.58
Weighted average grant date fair value per RSU	$	8.43		$	3.52		$	2.82
Based on our historical experience of options and restricted stock units that cancel before becoming fully vested, we have assumed an annualized forfeiture rate of 9.7% for all options and 6.8% for restricted stock units. Under the true-up provision of ASC 718, we will record additional expense if the actual forfeiture rate is lower than estimated, and will record a recovery of prior expense if the actual forfeiture rate is higher than estimated.
As of December 31, 2014, 2013 and 2012, the impact on our loss before income taxes as a result of stock-based compensation expense incurred was as follows:
	Year Ended December 31,
	2014			2013			2012
	(in thousands, except per share amounts)
Numerator:
Stock-based compensation	$	(4,037	)	$	(3,303	)	$	(3,747	)
Denominator:
Weighted average shares used in computing basic and diluted net loss per share		26,444,626			25,543,646			24,933,656
Impact of stock-based compensation per share	$	(0.15	)	$	(0.13	)	$	(0.15	)
Total compensation cost of options granted but not yet vested at December 31, 2014, 2013 and 2012 was approximately $2,744, $2,644 and $3,433, respectively, which is expected to be recognized over a weighted average period of 2.68 years, 2.14 and 2.34 years, respectively. Unvested stock options as of December 31, 2014 and 2013 were 1,102,930 and 1,491,574, respectively. As of December 31, 2014 and 2013, the weighted average grant date fair value per unvested option was $5.19 and $3.45, respectively.
The stock-based compensation expense related to unvested RSUs not yet recognized at December 31, 2014, 2013 and 2012 was approximately $1,979, $1,795 and $1,892, respectively, which is expected to be recognized over a weighted average period of 1.50 years, 1.31 years and 1.47 years, respectively. Unvested RSUs as of December 31, 2014 and 2013 were 864,634 and 857,656, respectively. As of December 31, 2014 and 2013, the weighted average grant date fair value per unvested RSU was $4.23 and $3.15, respectively.
Employee Stock Purchase Plan
In July 2008, we made available an employee stock purchase plan in which substantially all of our full-time employees became eligible to participate effective March 18, 2008. Under the plan, employees may contribute through payroll deductions up to 15% of their compensation toward the purchase of our common stock, or $21, whichever is lower. The price per share is equal to the lower of 85% of the fair market price on the first day of the offering period, or 85% of the fair market price on the day of purchase. Proceeds received from the issuance of shares are credited to stockholders' equity in the period that the shares are issued. In 2014, 346,245 shares were purchased in accordance with the Employee Stock Purchase Plan (ESPP). Net proceeds from the issuance of shares of common stock under the ESPP for the year ended December 31, 2014 were $871. In January 2014, the number of shares available for grant was increased by 258,240, per the ESPP plan documents. At December 31, 2014, approximately 428,151 shares remain available for purchase under the ESPP. For the years ended December 31, 2014, 2013 and 2012, we incurred ESPP expenses of $408, $211 and $182, respectively.
Option Acceleration
On December 1, 2009, we accelerated the vesting of certain employees' unvested options that were deeply out-of-the-money. The acceleration was done because we believed that there was no longer a compensation incentive tied to performance, given the exercise price of the options that were accelerated. Consistent with ASC 718, we continued to expense the accelerated options over the remaining service period. We do not have a static policy threshold to use for determining whether an option is deeply out-of-the-money. Rather, we believe that the determination should be made in light of current market conditions, probability of stock price recovery within the remaining service period, and historical volatility of our stock price. For the purposes of this option acceleration, we determined that options that were out-of-the-money by 30% or more were deeply out-of-the-money. As a result of the option acceleration, approximately 309,000 previously unvested shares became fully vested on December 1, 2009. We incurred an expense associated with the options that were accelerated in the amount of $0, $137 and $578 for the years ended December 31, 2014, 2013 and 2012, respectively, which have been recorded in the General and administrative line of the consolidated statement of operations.

Income_Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2014
Income Taxes
Income Taxes	10. Income Taxes
	We have deferred income tax assets totaling $57,314 at December 31, 2014, consisting primarily of federal and state net operating loss and credit carryforwards. Due to uncertainty regarding the ultimate realization of these net operating loss and credit carryforwards and other deferred income tax assets, we have established a full valuation allowance (net of deferred tax liabilities for indefinite lived intangibles) on our deferred tax assets and will recognize the benefits only as reassessment indicates the benefits are realizable. The determination of the required valuation allowance against net deferred tax assets was made without taking into account the deferred tax liabilities created from the book and tax differences on indefinite-lived assets.
	Our income tax benefit for 2014 of $2,313 primarily relates to a tax benefit due to the release of the Company's valuation allowance in the amount of $2,499 resulting from the corresponding recognition of a deferred tax liability on Mednet's opening balance sheet in accordance with ASC 805, Business Combinations.
	We performed an analysis to determine the extent to which we can use our net operating loss carryforwards and other deferred tax assets in future periods, subject to certain limitations imposed by the Internal Revenue Code. We concluded that largely because of our cumulative history of pre-tax losses in the most current three year period, it cannot predict that the benefits of the net operating loss carryforwards will be realized in future periods, and therefore we continue to provide a full valuation allowance for net deferred tax assets (exclusive of deferred tax liabilities for indefinite lived intangibles). We will perform a similar analysis during 2015 to reassess the ability to realize the net operating loss carryforwards and other deferred tax assets in the future
	Deferred taxes result from temporary differences between the carrying amounts of assets and liabilities used for financial reporting purposes and the amounts used for income tax purposes. The significant components of our deferred tax assets and liabilities are as follows:
		December 31,
		2014			2013
	Deferred tax assets:
	Net operating loss carryforwards	$	38,540		$	37,335
	Research & development and AMT credit carryforwards		5,314			4,687
	Stock option grants		7,410			6,533
	Allowance for doubtful accounts		4,532			3,101
	Other, net		1,518			1,928
	Total deferred tax assets		57,314			53,584
	Less valuation allowance		(52,998	)		(50,979	)
	Net deferred tax assets	$	4,316		$	2,605
	Deferred tax liabilities:
	Property, plant and equipment		(360	)		(345	)
	Identified intangible assets		(3,756	)		(2,089	)
	Indefinite lived intangible assets		(987	)		(730	)
	Prepaid insurance		(200	)		(171	)
	Total deferred tax liabilities		(5,303	)		(3,335	)
	Net deferred tax liability		(987	)		(730	)
	Reconciliations between expected income taxes computed at the federal rate of 35% for each of the years ended December 31, 2014, 2013 and 2012, and the provision (benefit) for income taxes is as follows:
		Years ended December 31,
		2014			2013			2012
	Income tax benefit at statutory rate	$	(4,237	)	$	(2,486	)	$	(4,587	)
	State income tax, net of federal benefit		4			716			(211	)
	Stock-based compensation		43			203			397
	Nondeductible goodwill impairment		—			—			—
	Other		(258	)		182			200
	Increase in valuation allowance		2,135			1,600			3,296
	Income tax (benefit) provision	$	(2,313	)	$	215		$	(905	)
	The increase in the valuation allowance in December 31, 2014 is the net of increases from the current year loss and credits generated and the release of the valuation allowance in accordance with ASC 805, Business Combinations, due to the Mednet acquisition accounting. At December 31, 2014, we had federal net operating loss carryforwards of approximately $100,997 to offset future federal taxable income expiring in various years starting in 2018 through 2034. At December 31, 2014, we had state net operating loss carryforwards of $47,776, which expire in various years starting in 2015 through 2034. Additionally, we have Research and Development credit carryforwards of $4,906 which begin to expire in 2021 through 2034.
	The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences are deductible. The timing and manner in which we can utilize our net operating loss carryforward and future income tax deductions in any year may be limited by provisions of the Internal Revenue Code regarding the change in ownership of corporations. Such limitation may have an impact on the ultimate realization of our carryforwards and future tax deductions. Section 382 of the Internal Revenue Code ("Section 382") imposes limitations on a corporation's ability to utilize net operating losses if it experiences an "ownership change." Section 383 of the Internal Revenue Code imposes similar limitations on other tax attributes such as research and development credits. In general terms, an ownership change may result from transactions increasing the ownership of certain stockholders in the stock of a corporation by more than 50 percentage points over a three-year period. Any unused annual limitation may be carried over to later years, and the amount of the limitation may under certain circumstances be increased by the built-in gains in assets held by us at the time of the change that are recognized in the five-year period after the change. Currently, a portion of our loss carryforwards is limited under Section 382.
	The components of our income tax (benefit) provision are summarized as follows:
		Year Ended December 31,
		2014			2013
	Current:
	Federal	$	—		$	24
	State		186			138
	Total current provision for income taxes		186			162
	Deferred:
	Federal		(2,355	)		—
	State		(144	)		53
	Total deferred provision (benefit) for income taxes		(2,499	)		53
	Total provision (benefit) for income taxes	$	(2,313	)	$	215
	The U.S. Internal Revenue Service concluded its examination of our U.S. federal tax returns for all years through 2010. Because of net operating losses, our U.S. federal tax returns statutes for those years will remain subject to examination until the losses are utilized. Additionally, state tax return statutes generally remain open due to operating losses.
	We do not have a tax reserve recorded for tax contingencies. As of December 31, 2014 and 2013, we have not identified any uncertain tax positions and therefore, it has no tax reserve recorded as of December 31, 2014 and 2013.

Commitments_and_Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies
Commitments and Contingencies	11. Commitments and Contingencies
	Leases
	We lease our principal administrative and service facilities as well as office equipment under non-cancelable operating leases expiring at various dates through 2021. The terms of the leases are renewable at the end of the lease term. Payments made under operating leases are charged to operations on a straight-line basis over the period of the lease. Differences between straight-line expense and cash payments are recognized in the deferred rent line of the balance sheet. Rent expense was $3,721, $3,622 and $2,946 for the years ended December 31, 2014, 2013 and 2012, respectively.
	We have entered into and acquired capital leases with various expiration dates through 2017 which were used to finance equipment, furniture and medical devices.
	Future minimum lease payments under non-cancelable operating and capital leases are summarized as follows at December 31, 2014:
		Operating		Capital
		Leases		Leases
	2015	$	3,277	$	480
	2016		2,941		287
	2017		2,836		101
	2018		2,770		—
	2019		1,357		—
	Thereafter		1,458		—
		$	14,639	$	868

Credit_Agreement

Credit Agreement	12 Months Ended
	Dec. 31, 2014
Credit Agreement
Credit Agreement	12. Credit Agreement
	Credit Agreement
	On December 30, 2014, we entered into a Credit Agreement with GE Capital, as agent for the lenders ("Lenders"), and as a Lender and swingline lender. Pursuant to the Credit Agreement, the Lenders agreed to make loans to us as follows; (i) Term Loans in an amount of $25,000 as of the closing date with an uncommitted ability to increase such Term Loans up to an amount not to exceed $10,000 , and (ii) Revolving Loans up to $15,000, which remain undrawn. The loan is recorded on our balance sheet in the amount of $24,008, which is net of an original issue discount of $992 related to fees paid to GE Capital.
	The GE Loans bear interest at an annual rate of LIBOR plus 4.0%, subject to a LIBOR floor of 1.0%. The outstanding principal of the Term Loan will be paid as follows:
	•	Beginning April 1, 2015, the principal amount of the Term Loan will be repaid, on a quarterly basis, in installments of $312, plus accrued interest;
	•	Beginning January 1, 2018, the principal amount of the Term Loan will be repaid, on a quarterly basis, in installments of $625, plus accrued interest;
	•	Beginning October 1, 2019, the remaining $16,563 will be paid in full on or before December 30, 2019, or such earlier date upon an acceleration of the Term Loan by the Lenders upon an event of default or termination by us.
	The Loans are secured by substantially all of our assets and by a pledge of the capital stock of our U.S. based subsidiaries as well as a pledge of 65% of the capital stock of Cardiocore Lab Ltd. and BioTelemetry Belgium.
	Covenants
	The Credit Agreement contains affirmative and financial covenants regarding the operations of our business and certain negative covenants that, among other things, limit our ability to incur additional indebtedness, grant certain liens, make certain investments, merge or consolidate, make certain restricted payments and engage in certain asset dispositions, including a sale of all, or substantially all, of our property. As of the closing date of the agreement, we were in compliance with our covenants.
	Debt Extinguishment
	In August 2012, we entered into a Credit and Security Agreement with MidCap Financial, LLC to provide revolving loan borrowings with a loan commitment of up to $15,000, and an option to increase to a maximum loan commitment of $30,000. We borrowed $8,000 in April 2014 to fund the BMS acquisition. If we terminated the Midcap Loan at any point prior to the loan expiration date of August 2016, we would incur a loan termination fee of 1.00% of the loan commitment due immediately preceding the termination.
	In February 2014, we entered into a Credit and Security Agreement with The Bancorp Bank for an aggregate amount of $9,830. The proceeds were used to pay off the assumed debt of $8,563 associated with the Mednet acquisition and to fund Mednet's working capital needs.
	In December 2014, we used the proceeds of the GE Loans to repay in full the $8,000 and $9,411 outstanding balances of the MidCap and Bancorp Loans, respectively. In connection with this repayment, we incurred a debt extinguishment loss of $372, included in Other (loss) income, net in our consolidated statements of operations. This loss includes a pre-payment penalty paid to Midcap as well as the write-off of the unamortized deferred financing fees related to the Midcap and Bancorp Loans.

Employee_Benefit_Plan

Employee Benefit Plan	12 Months Ended
	Dec. 31, 2014
Employee Benefit Plan
Employee Benefit Plan	13. Employee Benefit Plan
	We sponsor a 401(k) Retirement Savings Plan (the Plan) for all eligible employees who meet certain requirements. Participants may contribute, on a pre-tax basis, up to the maximum allowable amount pursuant to Section 401(k) of the Internal Revenue Code. We are not required to contribute to the Plan. In January 2012, we adopted an amendment to eliminate the employers' matching contribution. In January 2014, we adopted an amendment to the Plan that allowed for an employer matching contribution of 100% of the first 3% of the employees' salary, and 50% of the next 2% of the employees' salary. For the years ended December 31, 2014, 2013 and 2012, we contributed $1,483, $0 and $0, respectively. Employer contributions vest immediately.

Segment_Information

Segment Information	12 Months Ended
	Dec. 31, 2014
Segment Information
Segment Information	14. Segment Information
	We operate under three reportable segments: Patient Services, Product, and Research Services. The Patient Services segment is focused on the monitoring of cardiac arrhythmias or heart rhythm disorders with our comprehensive suite of cardiac monitoring solutions in a healthcare setting. The Product segment focuses on the development, manufacturing, testing and marketing of medical devices to medical companies, clinics and hospitals. Our Research Services segment is engaged in central core laboratory services providing cardiac monitoring, imaging, scientific consulting and data management services for drug and medical device trials. Intercompany revenue relating to the manufacturing of devices by the Product segment for the other segments is included on the intersegment revenue line.
	Expenses that can be specifically identified with a segment have been included as deductions in determining pre-tax segment income. Any remaining expenses including research and development costs incurred by the Product segment for the benefit of the other segments as well as the elimination of costs associated with intercompany revenue are included in Corporate and Other. Also included in Corporate and Other is the Department of Justice settlement, as well as interest expense, net and other financing expenses. We do not allocate assets to the individual segments. Mednet and BMS are primarily included in the Patient Services segment; with the product manufacturing and sales portions being included in the Product segment. RadCore is included in the Research Services segment.
		Patient		Research			Product		Corporate			Consolidated
		Services		Services					and Other
	2014
	Revenues	$	133,178	$	19,744		$	13,656	$	—		$	166,578
	Intersegment revenues		—		—			7,789		(7,789	)		—
	Income (loss) before income taxes		27,792		(701	)		6,681		(45,878	)		(12,106	)
	Depreciation and amortization		8,157		3,710			502		181			12,550
	Capital expenditures		11,488		1,077			216		—			12,781
		Patient		Research			Product		Corporate			Consolidated
		Services		Services					and Other
	2013
	Revenues	$	100,386	$	20,329		$	8,786	$	—		$	129,501
	Intersegment revenues		—		—			6,191		(6,191	)		—
	Income (loss) before income taxes		27,298		798			5,307		(40,507	)		(7,104	)
	Depreciation and amortization		4,253		4,057			551		3,457			12,318
	Capital expenditures		5,796		2,242			131		—			8,169

Legal_Proceedings

Legal Proceedings	12 Months Ended
	Dec. 31, 2014
Legal Proceedings
Legal Proceedings	15. Legal Proceedings
	From time to time, in the ordinary course of business and like others in the industry, we receive requests for information from government agencies in connection with their regulatory or investigational authority or are involved in traditional employment or business litigation. We review such requests and notices and take appropriate action.
	The final outcome of any current or future litigation or governmental or internal investigations cannot be accurately predicted, nor can we predict any resulting penalties, fines or other sanctions that may be imposed at the discretion of federal or state regulatory authorities. We record accruals for such contingencies to the extent that it concludes it is probable that a liability has been incurred and the amount of the loss can be projected.
	CardioNet v. Mednet Litigation
	On May 8, 2012, CardioNet, Inc. filed suit against Mednet Healthcare Technologies, Inc., MedTel 24, Inc., RhythmWatch LLC, and AMI Cardiac Monitoring, Inc., in the United States District Court for the Eastern District of Pennsylvania (Civil Action No. 2:12-CV-2517-JS) for patent infringement related to the making, use, offering for sale, and sale of the Heartrak ECAT device and monitoring services. The suit asserted that the defendants were infringing CardioNet's U.S. Patent Nos. 7,212,850, 7,907,996, 6,569,095, 7,587,237 and 7,941,207. CardioNet sought an injunction against each defendant, as well as monetary damages. The defendants asserted counterclaims alleging the patents in suit were invalid and not infringed.
	This litigation concluded on January 31, 2014 when the Court entered a Consent Judgment declaring all five CardioNet patents valid and enforceable, and infringed by the defendants' making, using, offering to sell, or selling the Heartrak ECAT device and monitoring services. The Consent Judgment also declared that all defendants are permanently enjoined from further infringement and are required to turn over all existing inventory of the Heartrak ECAT system to CardioNet and Braemar.
	Simultaneously with the entry on of the consent judgment BioTelemetry, through its CardioNet subsidiary, entered into a definitive stock purchase agreement, to purchase all of the outstanding capital stock of Mednet and its affiliated entities for consideration of $5,500 in cash and 96,649 shares of our common stock, valued at $705 at closing. In addition, as a result of the acquisition, we assumed indebtedness from the Mednet entities in the aggregate amount of $9,720, including interest.
	Under the terms of the Consent Judgment entered by the Court, Medtel 24 was granted a limited, non-exclusive, license for the Heartrak ECAT system for a period of one year. On the 364th day of such license, MedTel 24 filed a Motion to Set Aside the Consent Judgment and served the Company with a Demand for Arbitration. We are vigorously defending the claim and believe it to be without merit.
	CardioNet v. ScottCare Litigation
	On May 8, 2012, CardioNet, Inc. filed suit against The ScottCare Corporation and Ambucor Health Solutions, Inc. in the United States District Court for the Eastern District of Pennsylvania (Civil Action No. 2:12-CV-2516-PBT) for patent infringement under the same five CardioNet patents, as mentioned above in the Mednet litigation, related to the making, use, sale, and offering for sale of the ScottCare TeleSentry Mobile Cardiac Telemetry device and monitoring services. CardioNet is seeking an injunction against each defendant, as well as monetary damages. The ScottCare Corporation has asserted counterclaims alleging the patents in suit are invalid and not infringed.
	On May 10, 2013, CardioNet, Inc. and Braemar Manufacturing, LLC filed an Amended Complaint identifying Braemar as the new owner of all right, title and interest to the patents in suit with CardioNet as the exclusive licensee of these patents. Fact discovery closed on June 30, 2014, and the trial has been re-scheduled for June 8, 2015. Consistent with the accounting for contingent liabilities, no accrual has been recorded in the financial statements. We are vigorously pursuing our claims and defending against the counterclaims.

Civil_Investigative_Demand

Civil Investigative Demand	12 Months Ended
	Dec. 31, 2014
Civil Investigative Demand
Civil Investigative Demand	16. Civil Investigative Demand
	On August 25, 2011, we received a Civil Investigative Demand ("CID") issued by the U.S. Department of Justice, Western District of Washington. The CID states that it was issued in the course of an investigation under the Federal False Claims Act and seeks documents for the period January 1, 2007 through the date of the CID. The CID indicates that the investigation concerns allegations that we may have used inappropriate diagnosis codes when submitting claims for payment to Medicare for our real-time, MCOT™ services. During the second quarter of 2014, we reached an agreement in principle for a potential settlement; however, the pending settlement is subject to satisfactory negotiation and completion of a settlement agreement. As result, we recorded a non-operating charge of $6,400 in the first half of 2014. This reserve was recorded to Other (loss) income, net in the consolidated statements of operations and is included in Accrued liabilities on the balance sheet.
	The final outcome of any current or future litigation or governmental or internal investigations, including the potential settlement, cannot be accurately predicted, nor can we predict any resulting penalties, fines or other sanctions that may be imposed at the discretion of federal or state regulatory authorities. We record accruals for such contingencies to the extent that it concludes it is probable that a liability has been incurred and the amount of the loss can be projected.

Quarterly_Financial_Data_Unaud

Quarterly Financial Data (Unaudited)	12 Months Ended
	Dec. 31, 2014
Quarterly Financial Data (Unaudited)
Quarterly Financial Data (Unaudited)	17. Quarterly Financial Data (Unaudited)
	The following tables summarize the unaudited quarterly financial data for the last two fiscal years.
		First			Second			Third			Fourth
		Quarter			Quarter			Quarter			Quarter
		(in thousands, except per share amount)
	2014
	Total revenues	$	37,162		$	42,650		$	43,113		$	43,653
	Gross profit		21,644			23,613			23,678			24,529
	Integration, restructuring and other charges		2,980			1,000			1,045			2,073
	(Loss) income from operations		(3,696	)		(401	)		486			(702	)
	Net loss		(4,122	)		(3,988	)		(29	)		(1,654	)
	Basic and diluted net loss per share	$	(0.16	)	$	(0.15	)	$	(0.00	)	$	(0.06	)
	2013
	Total revenues	$	32,418		$	32,104		$	31,874		$	33,105
	Gross profit		19,545			19,496			19,234			20,795
	Integration, restructuring and other charges		1,202			2,541			3,077			1,162
	Income (loss) from operations		(2,034	)		(2,238	)		(2,835	)		226
	Net income (loss)		(2,087	)		(2,299	)		(2,956	)		23
	Basic and diluted net income (loss) per share	$	(0.08	)	$	(0.09	)	$	(0.12	)	$	0

Subsequent_Events

Subsequent Events	12 Months Ended
	Dec. 31, 2014
Subsequent Events
Subsequent Events	18. Subsequent Events
	None.

Schedule_IIAllowance_for_Doubt

Schedule II-Allowance for Doubtful Accounts	12 Months Ended
	Dec. 31, 2014
Schedule II-Allowance for Doubtful Accounts
Allowance for Doubtful Accounts	SCHEDULE II
		Beginning		Additions		Deductions			Ending
		Balance		Charged To		From			Balance
				Expense		Reserve
	Allowance for Doubtful Accounts
	Year ended December 31, 2014	$	7,640	$	9,347	$	(6,325	)	$	10,662
	Year ended December 31, 2013	$	7,617	$	7,787	$	(7,763	)	$	7,640
	Year ended December 31, 2012	$	9,889	$	11,912	$	(14,184	)	$	7,617

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2014
Summary of Significant Accounting Policies
Principles of Consolidation	Principles of Consolidation
	The accompanying consolidated financial statements include the accounts of BioTelemetry and its wholly owned subsidiaries. All significant intercompany transactions and balances have been eliminated in consolidation.
Use of Estimates	Use of Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires that management make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results may differ from those estimates.
Fair Value of Financial Instruments	Fair Value of Financial Instruments
	The fair value of financial instruments is defined as the amount at which the instrument could be exchanged in a current transaction between willing parties. Our financial instruments consist primarily of cash and cash equivalents, accounts receivable, other receivables, accounts payable, short-term and long-term debt. With the exception of the long-term debt, the carrying value of these financial instruments approximates their fair value because of their short-term nature (classified as Level 1). For long-term debt, based on the borrowing rates currently available, the carrying value also approximates fair value as of December 31, 2014 (classified as Level 2). The Company did not have any Level 3 assets or liabilities for the periods ended December 31, 2014 and 2013.
Cash and Cash Equivalents	Cash and Cash Equivalents
	Cash and cash equivalents are held in U.S. financial institutions or in custodial accounts with U.S. financial institutions. Cash equivalents are defined as liquid investments and money market funds with maturity from date of purchase of 90 days or less that are readily convertible into cash and have minimal interest rate risk.
Accounts Receivable and Allowance for Doubtful Accounts	Accounts Receivable and Allowance for Doubtful Accounts
	Accounts receivable related to the Patient Services segment are recorded at the time revenue is recognized, net of contractual allowances, and are presented on the balance sheet net of allowance for doubtful accounts. The ultimate collection of accounts receivable may not be known for several months after services have been provided and billed. We record allowance for doubtful accounts based on the aging of receivables using historical data. The percentages and amounts used to record bad debt expense and the allowance for doubtful accounts are supported by various methods and analyses, including current and historical cash collections, and the aging of receivables by payor. Because of continuing changes in the health care industry and third party reimbursement, it is possible that our estimates of collectability could change, which could have a material impact on our operations and cash flows.
	Other receivables related to the Product and Research Services segments are recorded at the time revenue is recognized, or when products are shipped or services are performed. We estimate allowance for doubtful accounts on a specific account basis, and consider several factors in our analysis including customer specific information and aging of the account.
	We write off receivables when the likelihood for collection is remote and when we believe collection efforts have been fully exhausted and we do not intend to devote additional resources in attempting to collect. We perform write-offs on a monthly basis. In the Patient Services segment, we wrote off $6,494 and $7,919 of receivables for the years ended December 31, 2014 and 2013, respectively. The impact was a reduction of gross receivables and a reduction in the allowance for doubtful accounts. There were no material write offs in the Product and Research Services segments. Additionally, we recorded bad debt expense of $9,347, $7,787 and $11,912 for the years ended December 31, 2014, 2013, and 2012, respectively. Unfavorable adjustments of $782 and $1,480 were made to accounts receivable in 2014 and 2013, respectively, related to prior years accounts receivable.
Concentrations of Credit Risk	Concentrations of Credit Risk
	Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash, cash equivalents and accounts receivable. We maintain our cash and cash equivalents with high quality financial institutions to mitigate this risk. We perform ongoing credit evaluations of our customers and generally do not require collateral. We record an allowance for doubtful accounts in accordance with the procedures described above. Past-due amounts are written off against the allowance for doubtful accounts when collections are believed to be unlikely and all collection efforts have ceased.
	At December 31, 2014, 2013 and 2012, one customer, Medicare, accounted for 16%, 18% and 20%, respectively, of our net accounts receivable.
Inventory	Inventory
	Inventory is valued at the lower of cost (using first-in, first-out cost method) or market (net realizable value or replacement cost). Management periodically reviews inventory for specific future usage, and estimates of impairment of individual inventory items are recorded to reduce inventory to the lower of cost or market.
Property and Equipment	Property and Equipment
	Property and equipment is recorded at cost. Depreciation is recorded over the estimated useful life of each class of depreciable assets, and is computed using the straight-line method. Leasehold improvements are amortized over the shorter of the estimated asset life or term of the lease. Repairs and maintenance costs are charged to expense as incurred.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets
	We periodically evaluate the recoverability of the carrying value of our long-lived assets based on the criteria established in Accounting Standards Codification (ASC) 360, Property, Plant & Equipment. We consider historical performance and anticipated future results in our evaluation of potential impairment. Accordingly, when indicators of impairment are present, we evaluate the carrying value of these assets in relation to the operating performance of the business and the undiscounted cash flows expected to result from the use of these assets. Impairment losses are recognized when the sum of the expected future cash flows is less than the assets' carrying value.
Goodwill and Acquired Intangible Assets	Goodwill and Acquired Intangible Assets
	Goodwill is the excess of purchase price of an acquired business over the amounts assigned to assets acquired and liabilities assumed in a business combination. In accordance with ASC 350, Intangibles—Goodwill and Other, goodwill is reviewed for impairment annually, or when events arise that could indicate that impairment exists. The provisions of ASC 350 require that we perform a two-step impairment test. In the first step, we compare the fair value of our reporting units to the carrying value of the reporting units. If the carrying value of the net assets assigned to the reporting units exceeds the fair value of the reporting units, then the second step of the impairment test is performed in order to determine the implied fair value of the reporting units' goodwill. If the carrying value of the reporting units' goodwill exceeds the implied fair value, an impairment loss equal to the difference is recorded.
	For the purpose of performing our goodwill impairment analysis in 2014, we consider our business to be comprised of three reporting units, Patient Services, Product and Research Services. We calculate the fair value of the reporting units utilizing a weighting of the income and market approaches. The income approach is based on a discounted cash flow methodology that includes assumptions for, among other things, forecasted income, cash flow, growth rates, income tax rates, expected tax benefits and long-term discount rates, all of which require significant judgment. The market approach utilizes our market data as well as market data from publicly traded companies that are similar to us. There are inherent uncertainties related to these factors and the judgment applied in the analysis. We believe that the combination of an income and a market approach provides a reasonable basis to estimate the fair value of our reporting units.
Revenue Recognition	Revenue Recognition
	We recognize approximately 80% of our total revenue from patient monitoring services in our Patient Services segment. We receive a significant portion of our revenue from third party commercial payors and governmental entities. We also receive reimbursement directly from patients through co-pay, deductibles and self-pay arrangements.
	Revenue from the Medicare program is based on reimbursement rates set by CMS. Revenue from contracted commercial payors is recorded at the negotiated contractual rate. Revenue from non-contracted commercial payors is recorded at net realizable value based on historical payment patterns. Adjustments to the estimated net realizable value, based on final settlement with the third party payors, are recorded upon settlement. If we do not have consistent historical information regarding collectability from a given payor, revenue is recognized when cash is received. Unearned amounts are appropriately deferred until service has been completed. For the years ended December 31, 2014, 2013 and 2012, revenue from Medicare as a percentage of total revenue was 32%, 35% and 37%, respectively.
	Revenue received from the sale of products, product repair and supplies is recognized when shipped, or as service is completed.
	Research Services revenue includes revenue for research and core laboratory services. Our Research Services revenues are provided on a fee for service basis, and revenue is recognized as the related services are performed. We also provide consulting services on a time and materials basis and recognize revenues as we perform the services. Our site support revenue, consisting of equipment rentals and sales along with related supplies and logistics management, are recognized at the time of sale or over the rental period. Under a typical contract, customers pay us a portion of our fee for these services upon contract execution as an upfront deposit, some of which is typically nonrefundable upon contract termination. Unearned revenues, including upfront deposits, are deferred, and then recognized as the services are performed.
	For arrangements with multiple deliverables, the revenue is allocated to each element (both delivered and undelivered items) based on their relative selling prices or management's best estimate of their selling prices, when vendor- specific or third-party evidence is unavailable.
	We record reimbursements received for out-of-pocket expenses, including freight, incurred as revenue in the accompanying consolidated statements of operations. Revenue generally is recognized net of any taxes collected from customers and subsequently remitted to government authorities.
Research and Development Costs	Research and Development Costs
	Research and development costs are charged to expense as incurred.
Net Loss	Net Loss
	We compute net loss per share in accordance with ASC 260, Earnings Per Share. The following summarizes the potential outstanding common stock as of the end of each period:
		December 31,			December 31,			December 31,
		2014			2013			2012
	Employee stock purchase plan estimated share options outstanding		39,232			81,848			50,903
	Common stock options and restricted stock units ("RSUs") outstanding		4,115,486			3,993,590			3,669,103
	Common stock available for grant		2,262,168			1,761,840			1,442,434
	Common stock		26,693,248			25,812,754			25,189,340
	Total		33,110,134			31,650,032			30,351,780
	Basic net loss per share is computed by dividing net loss by the weighted average number of fully vested common shares outstanding during the period. Diluted net loss per share is computed by giving effect to all potential dilutive common shares, including stock options, and RSUs.
	The following table presents the calculation of historical basic and diluted net loss per share:
		Year Ended December 31,
		2014			2013			2012
		(in thousands, except per share amounts)
	Numerator:
	Net loss	$	(9,793	)	$	(7,319	)	$	(12,202	)
	Denominator:
	Weighted average shares used in computing basic and diluted net loss per share		26,444,626			25,543,646			24,933,656
	Basic and diluted net loss per share	$	(0.37	)	$	(0.29	)	$	(0.49	)
	If the outstanding vested options or RSUs were exercised or converted into common stock, the result would be anti-dilutive for the years ended December 31, 2014, 2013 and 2012. Accordingly, basic and diluted net loss per share are the same for the years ended December 31, 2014, 2013 and 2012.
Stock-Based Compensation	Stock-Based Compensation
	ASC 718, Compensation—Stock Compensation, addresses the accounting for share-based payment transactions in which an enterprise receives employee services in exchange for (a) equity instruments of the enterprise or (b) liabilities that are based on the fair value of the enterprise's equity instruments or that may be settled by the issuance of such equity instruments. ASC 718 requires that an entity measures the cost of equity-based service awards based on the grant-date fair value of the award and recognizes the cost of such awards over the period during which the employee is required to provide service in exchange for the award (the vesting period). ASC 718 requires that an entity measures the cost of liability-based service awards based on current fair value that is re-measured subsequently at each reporting date through the settlement date. We account for equity awards issued to non-employees in accordance with ASC 505-50, Equity-Based Payments to Non-Employees.
Income Taxes	Income Taxes
	We account for income taxes under the liability method, as described in ASC 740, Income Taxes. Deferred income taxes are recognized for the tax consequences of temporary differences between the tax and financial statement reporting bases of assets and liabilities. A valuation allowance for net deferred tax assets is provided unless realizability is judged to be more likely than not.
Segment Information	Segment Information
	ASC 280, Segment Reporting, establishes standards for reporting information regarding operating segments in annual financial statements. Operating segments are identified as components of an enterprise for which separate discrete financial information is available for evaluation by the chief operating decision-maker, or decision-making group in making decisions on how to allocate resources and assess performance.
	We report our business under three segments: Patient Services, Product and Research Services. The Patient Services segment is focused on the monitoring of cardiac arrhythmias or heart rhythm disorders in a healthcare setting. The Product segment focuses on the development, manufacturing, testing and marketing of medical devices to medical companies, clinics and hospitals. The Research Services segment includes our operations that engage in central core laboratory services in a research environment, which includes certain equipment rental and Product sales. In addition, we realigned the Product segment to exclude central core laboratory research operations previously reported in this segment and repositioned these operations into the Research Services segment.
Recent Accounting Pronouncements	Recent Accounting Pronouncements
	In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers, which provides guidance for revenue recognition. The new standard will require revenue recognized to represent the transfer of promised goods or services to customers in an amount that reflects the consideration in which we expect to receive in exchange for those goods or services. The standard also requires new, expanded disclosures regarding revenue recognition and is effective for the annual reporting periods beginning after December 15, 2016. We are currently evaluating the impact the adoption of this standard will have on the consolidated financial statements.
	In July 2013, the FASB issued ASU 2013-11, Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists. The new guidance provides specific financial statement presentation requirements of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. The guidance states that an unrecognized tax benefit in those circumstances should be presented as a reduction to the deferred tax asset. The ASU is effective for fiscal years, and interim periods within those years, beginning after December 15, 2013. The amendment did not have a material impact on our results of operations, cash flows, or financial position.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2014
Summary of Significant Accounting Policies
Summary of potential outstanding common stock
		December 31,			December 31,			December 31,
		2014			2013			2012
	Employee stock purchase plan estimated share options outstanding		39,232			81,848			50,903
	Common stock options and restricted stock units ("RSUs") outstanding		4,115,486			3,993,590			3,669,103
	Common stock available for grant		2,262,168			1,761,840			1,442,434
	Common stock		26,693,248			25,812,754			25,189,340
	Total		33,110,134			31,650,032			30,351,780
Schedule of calculation of basic and diluted net loss per share
		Year Ended December 31,
		2014			2013			2012
		(in thousands, except per share amounts)
	Numerator:
	Net loss	$	(9,793	)	$	(7,319	)	$	(12,202	)
	Denominator:
	Weighted average shares used in computing basic and diluted net loss per share		26,444,626			25,543,646			24,933,656
	Basic and diluted net loss per share	$	(0.37	)	$	(0.29	)	$	(0.49	)

Business_Combinations_Tables

Business Combinations (Tables)	12 Months Ended
	Dec. 31, 2014
BMS
Business Acquisition
Schedule of purchase price allocation	The amounts below represent the preliminary fair value estimates as of December 31, 2014 and are subject to subsequent adjustment as additional information is obtained during the measurement period.
	Fair value of assets acquired:
	Property and equipment	$	882
	Goodwill		3,559
	Intangible assets		4,209
	Net assets acquired	$	8,650
Schedule of estimated allocation of finite-lived intangible assets
		Estimated			Fair Value
		Useful Life
		(Years)
	Customer relationships		15		$	2,100
	Technology		4			1,849
	Covenants not to compete		7			260
	Total intangible assets				$	4,209
Mednet
Business Acquisition
Schedule of purchase price allocation	The amounts below represent the preliminary fair value estimates as of December 31, 2014 and are subject to subsequent adjustment as additional information is obtained during the measurement period.
	Fair value of assets acquired:
	Cash and cash equivalents	$	(199	)
	Accounts receivable		3,879
	Inventory		311
	Property and equipment		3,429
	Goodwill		9,354
	Intangible assets		9,220
	Other assets		317
	Total assets acquired		26,311
	Liabilities assumed:
	Accounts payable		4,427
	Accrued expenses		2,932
	Other liabilities		3,027
	Long-term debt, capital leases, note payable and related interest		9,720
	Total liabilities assumed		20,106
	Net assets acquired	$	6,205
Schedule of allocation of finite-lived and indefinite-lived intangible assets
		Estimated			Fair Value
		Useful Life
		(Years)
	Customer relationships		13		$	6,500
	Technology		5			1,600
	Covenants not to compete		5			420
	Indefinite-lived trade name					700
	Total intangible assets				$	9,220
Schedule of unaudited pro forma information representing combined results of operations as if the acquisition had occurred at the beginning of the periods presented
		December 31,
		2014			2013
	Revenue	$	170,076		$	155,415
	Net Loss	$	(8,014	)	$	(8,604	)
	Net loss per common share:
	Basic and Diluted	$	(0.30	)	$	(0.34	)
	Weighted average number of shares:
	Basic		26,444,626			25,640,295
Cardiocore
Business Acquisition
Schedule of unaudited pro forma information representing combined results of operations as if the acquisition had occurred at the beginning of the periods presented
		December 31,
		2012
	Revenue	$	124,698
	Net Income (Loss)	$	(10,936	)
	Net Income per common share:
	Basic and Diluted	$	(0.47	)
	Weighted average number of shares:
	Basic		24,933,656

Inventory_Tables

Inventory (Tables)	12 Months Ended
	Dec. 31, 2014
Inventory
Schedule of inventory
		December 31,
		2014		2013
	Raw materials and supplies	$	2,347	$	2,404
	Finished goods		219		150
	Total inventories	$	2,566	$	2,554

Property_and_Equipment_Tables

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2014
Property and Equipment
Schedule of Property and equipment
			December 31,
		Estimated
		Useful Life
		(Years)	2014			2013
	Cardiac monitoring devices, device parts and components	3 - 5	$	47,190		$	37,273
	Computers and purchased software	3 - 5		12,614			13,302
	Equipment, tools and molds	3 - 5		5,543			5,384
	Furniture and fixtures	7		1,396			2,863
	Leasehold improvements	Life of lease		2,930			2,665
	Capital leases	3 - 7		1,884			737
	Total property and equipment, at cost			71,557			62,224
	Less accumulated depreciation			(49,854	)		(43,445	)
	Total property and equipment, net		$	21,703		$	18,779

Goodwill_and_Intangible_Assets1

Goodwill and Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2014
Goodwill and Intangible Assets
Schedule of changes in the carrying amounts of goodwill by segment
		Reporting Segment
		Patient			Research			Product		Total
		Services			Services
	Balance at December 31, 2013	$	1,577		$	11,735		$	3,157	$	16,469
	Goodwill acquired during the year		12,912			215			—		13,127
	Balance at December 31, 2014	$	14,489		$	11,950		$	3,157	$	29,596
Schedule of gross carrying amounts and accumulated amortization of the entity's intangible assets
				December 31,
		Estimated
		Useful Life
		(Years)		2014			2013
	Customer relationships	5 - 15		$	10,700		$	2,100
	Technology including internally developed software	3 - 5			12,649			4,000
	Signed backlog	1 - 4			3,160			2,800
	Unsigned backlog	4			600			600
	Covenants not to compete	5 - 7			1,040			360
	Total intangible assets, gross				28,149			9,860
	Customer relationships accumulated amortization				(1,556	)		(722	)
	Proprietary technology accumulated amortization				(3,855	)		(1,902	)
	Signed backlog accumulated amortization				(1,984	)		(1,400	)
	Unsigned backlog accumulated amortization				(350	)		(200	)
	Covenants not to compete accumulated amortization				(295	)		(124	)
	Total accumulated amortization				(8,040	)		(4,348	)
	Indefinite-lived trade name				2,500			1,800
	In-process internally developed software				111			—
	Total intangible assets, net			$	22,720		$	7,312
Summary of estimated amortization expense for the next five years	The estimated amortization expense for the next five years is summarized as follows at December 31, 2014:
	2015	$	4,628
	2016		3,531
	2017		2,828
	2018		2,342
	2019		1,768
	Thereafter		5,012
	Total intangibles assets, net	$	20,109

Accrued_Expenses_Tables

Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2014
Accrued Expenses
Schedule of accrued expenses
		December 31,
		2014		2013
	Accrued compensation	$	5,296	$	4,932
	Accrued professional fees		8,289		1,922
	Accrued purchases		977		311
	Accrued restructuring costs		689		96
	Other		3,209		929
	Total	$	18,460	$	8,190

Integration_Restructuring_and_1

Integration, Restructuring and Other Charges (Tables)	12 Months Ended
	Dec. 31, 2014
Integration, Restructuring and Other Charges
Summary of expenses related to restructuring, integration and other activities
		Year ended December 31,
		2014		2013		2012
	Legal fees	$	4,691	$	5,516	$	1,780
	Severance and employee related costs		1,738		1,410		1,490
	Professional fees		669		492		778
	Expenses related to facility closure		—		564		—
	Other charges		—		—		188
	Total	$	7,098	$	7,982	$	4,236

Shareholders_Equity_Tables

Shareholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2014
Shareholders' Equity
Summary of stock option under all equity incentive plans
		Number			Weighted
		of Shares			Average
					Exercise Price
	Options outstanding as of December 31, 2011		1,846,911		$	10.11
	Granted		1,387,560		$	2.68
	Cancelled		(326,458	)	$	11.34
	Exercised		(2,252	)	$	1.61
	Options outstanding as of December 31, 2012		2,905,761		$	6.44
	Granted		729,439		$	3.24
	Cancelled		(393,770	)	$	5.93
	Exercised		(105,496	)	$	4.43
	Options outstanding as of December 31, 2013		3,135,934		$	5.83
	Granted		582,012		$	8.45
	Cancelled		(310,303	)	$	6.55
	Exercised		(156,791	)	$	3.37
	Options outstanding as of December 31, 2014		3,250,852		$	6.4
Summary of total outstanding stock options	A summary of total outstanding stock options as of December 31, 2014 is as follows:
		Options Outstanding									Options Exercisable
	Range of Exercise Price	Number			Weighted			Weighted			Number		Weighted		Weighted
		Outstanding			Average			Average			Exercisable		Average		Average
					Remaining			Exercise Price					Remaining		Exercise Price
					Contractual								Contractual
					Life (in years)								Life (in years)
	$0.70 - $7.50		2,478,630			6.80		$	4.08			1,750,230		6.37	$	4.43
	$7.51 - $15.00		473,475			8.86		$	8.94			98,945		7.70	$	8.93
	$15.01 - $22.50		218,347			4.28		$	18.42			218,347		4.28	$	18.42
	$22.51 - $31.18		80,400			3.62		$	30.17			80,400		3.62	$	30.17
	$0.70 - $31.18		3,250,852			6.82		$	6.40			2,147,922		6.11	$	7.02
Summary of certain additional information with respect to options
	(In thousands)	2014			2013			2012
	Aggregate intrinsic value of options outstanding at year-end	$	15,258		$	11,183		$	46
	Aggregate intrinsic value of options exercisable at year-end		9,918			4,382			13
	Aggregate intrinsic value of options exercised during the year		840			422			2
Summary of Restricted stock units activity
		Number			Weighted Average
		of Shares			Grant Date Fair
					Value
	Restricted stock outstanding as of December 31, 2011		622,080		$	8.17
	Granted		741,379		$	2.82
	Forfeited		(69,854	)	$	3.45
	Vested		(530,263	)	$	8.03
	Restricted stock outstanding as of December 31, 2012		763,342		$	3.54
	Granted		457,200		$	3.52
	Forfeited		(82,813	)	$	3.07
	Vested		(280,073	)	$	4.82
	Restricted stock outstanding as of December 31, 2013		857,656		$	3.15
	Granted		292,079		$	8.48
	Forfeited		(89,664	)	$	3.3
	Vested		(195,437	)	$	6.27
	Restricted stock outstanding as of December 31, 2014		864,634		$	3.68
Summary of total outstanding RSUs	In addition, a summary of total outstanding RSUs as of December 31, 2014 is as follows:
	Range of Grant Price	RSUs
		Outstanding
	$2.16 - $6.75		632,201
	$6.76 - $9.75		232,433
	$2.16 - $9.75		864,634
Schedule of weighted average assumptions used to estimate the fair value of the stock-based awards
		Year Ended
		December 31,
		2014			2013			2012
	Expected volatility		62.8	%		60.3	%		63.4	%
	Expected term (in years)		6.49			6.71			6.31
	Weighted average risk-free interest rate		1.85	%		1.34	%		1.15	%
	Expected dividends		0.0	%		0.0	%		0.0	%
	Weighted average grant date fair value per option	$	5.00		$	1.90		$	1.58
	Weighted average grant date fair value per RSU	$	8.43		$	3.52		$	2.82
Schedule of impact of stock-based compensation on entity's loss before income taxes
		Year Ended December 31,
		2014			2013			2012
		(in thousands, except per share amounts)
	Numerator:
	Stock-based compensation	$	(4,037	)	$	(3,303	)	$	(3,747	)
	Denominator:
	Weighted average shares used in computing basic and diluted net loss per share		26,444,626			25,543,646			24,933,656
	Impact of stock-based compensation per share	$	(0.15	)	$	(0.13	)	$	(0.15	)

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2014
Income Taxes
Schedule of the components of the entity's deferred tax assets and liabilities
		December 31,
		2014			2013
	Deferred tax assets:
	Net operating loss carryforwards	$	38,540		$	37,335
	Research & development and AMT credit carryforwards		5,314			4,687
	Stock option grants		7,410			6,533
	Allowance for doubtful accounts		4,532			3,101
	Other, net		1,518			1,928
	Total deferred tax assets		57,314			53,584
	Less valuation allowance		(52,998	)		(50,979	)
	Net deferred tax assets	$	4,316		$	2,605
	Deferred tax liabilities:
	Property, plant and equipment		(360	)		(345	)
	Identified intangible assets		(3,756	)		(2,089	)
	Indefinite lived intangible assets		(987	)		(730	)
	Prepaid insurance		(200	)		(171	)
	Total deferred tax liabilities		(5,303	)		(3,335	)
	Net deferred tax liability		(987	)		(730	)
Schedule of reconciliations between expected income taxes computed at the federal rate and the provision (benefit) for income taxes
		Years ended December 31,
		2014			2013			2012
	Income tax benefit at statutory rate	$	(4,237	)	$	(2,486	)	$	(4,587	)
	State income tax, net of federal benefit		4			716			(211	)
	Stock-based compensation		43			203			397
	Nondeductible goodwill impairment		—			—			—
	Other		(258	)		182			200
	Increase in valuation allowance		2,135			1,600			3,296
	Income tax (benefit) provision	$	(2,313	)	$	215		$	(905	)
Schedule of the components of the entity's income tax (benefit) provision
		Year Ended December 31,
		2014			2013
	Current:
	Federal	$	—		$	24
	State		186			138
	Total current provision for income taxes		186			162
	Deferred:
	Federal		(2,355	)		—
	State		(144	)		53
	Total deferred provision (benefit) for income taxes		(2,499	)		53
	Total provision (benefit) for income taxes	$	(2,313	)	$	215

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies
Summary of the future minimum lease payments under non-cancelable operating and capital leases	Future minimum lease payments under non-cancelable operating and capital leases are summarized as follows at December 31, 2014:
		Operating		Capital
		Leases		Leases
	2015	$	3,277	$	480
	2016		2,941		287
	2017		2,836		101
	2018		2,770		—
	2019		1,357		—
	Thereafter		1,458		—
		$	14,639	$	868

Segment_Information_Tables

Segment Information (Tables)	12 Months Ended
	Dec. 31, 2014
Segment Information
Summary of financial information concerning the entity's reportable segments
		Patient		Research			Product		Corporate			Consolidated
		Services		Services					and Other
	2014
	Revenues	$	133,178	$	19,744		$	13,656	$	—		$	166,578
	Intersegment revenues		—		—			7,789		(7,789	)		—
	Income (loss) before income taxes		27,792		(701	)		6,681		(45,878	)		(12,106	)
	Depreciation and amortization		8,157		3,710			502		181			12,550
	Capital expenditures		11,488		1,077			216		—			12,781
		Patient		Research			Product		Corporate			Consolidated
		Services		Services					and Other
	2013
	Revenues	$	100,386	$	20,329		$	8,786	$	—		$	129,501
	Intersegment revenues		—		—			6,191		(6,191	)		—
	Income (loss) before income taxes		27,298		798			5,307		(40,507	)		(7,104	)
	Depreciation and amortization		4,253		4,057			551		3,457			12,318
	Capital expenditures		5,796		2,242			131		—			8,169

Quarterly_Financial_Data_Unaud1

Quarterly Financial Data (Unaudited) (Tables)	12 Months Ended
	Dec. 31, 2014
Quarterly Financial Data (Unaudited)
Summary of the unaudited quarterly financial data
		First			Second			Third			Fourth
		Quarter			Quarter			Quarter			Quarter
		(in thousands, except per share amount)
	2014
	Total revenues	$	37,162		$	42,650		$	43,113		$	43,653
	Gross profit		21,644			23,613			23,678			24,529
	Integration, restructuring and other charges		2,980			1,000			1,045			2,073
	(Loss) income from operations		(3,696	)		(401	)		486			(702	)
	Net loss		(4,122	)		(3,988	)		(29	)		(1,654	)
	Basic and diluted net loss per share	$	(0.16	)	$	(0.15	)	$	(0.00	)	$	(0.06	)
	2013
	Total revenues	$	32,418		$	32,104		$	31,874		$	33,105
	Gross profit		19,545			19,496			19,234			20,795
	Integration, restructuring and other charges		1,202			2,541			3,077			1,162
	Income (loss) from operations		(2,034	)		(2,238	)		(2,835	)		226
	Net income (loss)		(2,087	)		(2,299	)		(2,956	)		23
	Basic and diluted net income (loss) per share	$	(0.08	)	$	(0.09	)	$	(0.12	)	$	0

Organization_and_Description_o1

Organization and Description of Business (Details)	12 Months Ended
	Dec. 31, 2014
	segment
Organization and Description of Business
Number of operating segments	3

Summary_of_Significant_Account3

Summary of Significant Accounting Policies (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Accounts receivable and allowance for doubtful accounts
Bad debt expense	$9,347	$7,787	$11,912
Unfavorable adjustments related to prior year's accounts receivable	782	1,480
Patient Services
Accounts receivable and allowance for doubtful accounts
Write-off of receivables	$6,494	$7,919

Summary_of_Significant_Account4

Summary of Significant Accounting Policies (Details 2) (Net accounts receivable, Credit concentration risk)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Concentrations of credit risk
Number of major customers	1
Medicare
Concentrations of credit risk
Concentration risk (as a percent)	16.00%	18.00%	20.00%

Summary_of_Significant_Account5

Summary of Significant Accounting Policies (Details 3)	12 Months Ended	30 Months Ended	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
	segment	segment
Goodwill and Acquired Intangible Assets
Number of reporting units	3	3
Revenue | Service concentration | Patient monitoring services
Revenue Recognition
Concentration risk (as a percent)	80.00%
Revenue | Payor concentration | Medicare
Revenue Recognition
Concentration risk (as a percent)	32.00%		35.00%	37.00%

Summary_of_Significant_Account6

Summary of Significant Accounting Policies (Details 4) (USD $)	3 Months Ended								12 Months Ended			30 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2014
									segment			segment
Potential outstanding common stock
Employee stock purchase plan estimated share options outstanding (in shares)	39,232				81,848				39,232	81,848	50,903	39,232
Common stock options and restricted stock units ("RSUs") outstanding (in shares)	4,115,486				3,993,590				4,115,486	3,993,590	3,669,103	4,115,486
Common stock available for grant (in shares)	2,262,168				1,761,840				2,262,168	1,761,840	1,442,434	2,262,168
Common stock (in shares)	26,693,248				25,812,754				26,693,248	25,812,754	25,189,340	26,693,248
Total (in shares)	33,110,134				31,650,032				33,110,134	31,650,032	30,351,780	33,110,134
Calculation of basic and diluted net loss per share
Numerator: Net loss (in dollars)	($1,654)	($29)	($3,988)	($4,122)	$23	($2,956)	($2,299)	($2,087)	($9,793)	($7,319)	($12,202)
Denominator: Weighted average shares used in computing basic and diluted net loss per share									26,444,626	25,543,646	24,933,656
Basic and diluted net loss per share	($0.06)	$0	($0.15)	($0.16)	$0	($0.12)	($0.09)	($0.08)	($0.37)	($0.29)	($0.49)
Segment Information
Number of reportable segments									3			3

Business_Combinations_Details

Business Combinations (Details) (RadCore, Cardiocore, USD $)	0 Months Ended
In Thousands, except Share data, unless otherwise specified	Jun. 03, 2014
RadCore | Cardiocore
Business Acquisition
Purchase consideration in cash	$400
Number of shares of common stock issued for acquisition	22,513
Value of common stock issued for acquisition	$200

Business_Combinations_Details_

Business Combinations (Details 2) (USD $)	0 Months Ended	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Apr. 03, 2014	Dec. 31, 2014	Dec. 31, 2013
Fair value of assets acquired:
Goodwill		$29,596	$16,469
BMS | CardioNet
Business Acquisition
Purchase consideration in cash	8,000
Number of shares of common stock issued for acquisition	62,859
Value of common stock issued for acquisition	650
Fair value of assets acquired:
Property and equipment		882
Goodwill		3,559
Intangible assets		4,209
Net assets acquired		8,650
BMS | CardioNet | Customer relationships
Fair value of assets acquired:
Intangible assets		2,100
Estimated Useful Life		15 years
BMS | CardioNet | Technology
Fair value of assets acquired:
Intangible assets		1,849
Estimated Useful Life		4 years
BMS | CardioNet | Covenants not to compete
Fair value of assets acquired:
Intangible assets		$260
Estimated Useful Life		7 years

Business_Combinations_Details_1

Business Combinations (Details 3) (USD $)	12 Months Ended		0 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Jan. 31, 2014
Fair value of assets acquired:
Goodwill	$29,596	$16,469
Mednet
Liabilities assumed:
Long-term debt, capital leases, note payable and related interest			9,720
Pro-Forma Information
Revenue from acquisition	23,355
Revenue	170,076	155,415
Net Loss	-8,014	-8,604
Net loss per common share: Basic and Diluted (in dollars per share)	($0.30)	($0.34)
Weighted average number of shares: Basic	26,444,626	25,640,295
Mednet | CardioNet
Business Acquisition
Purchase consideration in cash			5,500
Number of shares of common stock issued for acquisition			96,649
Value of common stock issued for acquisition			705
Fair value of assets acquired:
Cash and cash equivalents	-199
Accounts receivable	3,879
Inventory	311
Property and equipment	3,429
Goodwill	9,354
Intangible assets	9,220
Other assets	317
Total assets acquired	26,311
Liabilities assumed:
Accounts payable	4,427
Accrued expenses	2,932
Other liabilities	3,027
Long-term debt, capital leases, note payable and related interest	9,720
Total liabilities assumed	20,106
Net assets acquired	6,205
Mednet | CardioNet | Indefinite-lived trade name
Fair value of assets acquired:
Intangible assets	700
Mednet | CardioNet | Customer relationships
Fair value of assets acquired:
Intangible assets	6,500
Estimated Useful Life	13 years
Mednet | CardioNet | Technology
Fair value of assets acquired:
Intangible assets	1,600
Estimated Useful Life	5 years
Mednet | CardioNet | Covenants not to compete
Fair value of assets acquired:
Intangible assets	$420
Estimated Useful Life	5 years

Business_Combinations_Details_2

Business Combinations (Details 4) (USD $)	0 Months Ended	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Aug. 29, 2012	Dec. 31, 2012	Dec. 31, 2014	Dec. 31, 2013
Fair value of assets acquired:
Goodwill			$29,596	$16,469
Cardiocore
Business Acquisition
Aggregate cash purchase price	23,500
Pro-Forma Information
Revenue		124,698
Net Income (Loss)		($10,936)
Net Income per common share: Basic and Diluted (in dollars per share)		($0.47)
Weighted average number of shares: Basic		24,933,656

Business_Combinations_Details_3

Business Combinations (Details 5) (USD $)	0 Months Ended
In Thousands, unless otherwise specified	Feb. 10, 2012	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Fair value of assets acquired:
Goodwill		$29,596	$16,469
ECG Scanning
Business Acquisition
Aggregate cash purchase price	5,800
Additional cash to be paid upon the achievement of certain performance targets	600
Estimated fair value	$570			$0
Period for achievement of performance target upon which cash is required to be paid	1 year

Inventory_Details

Inventory (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Inventory
Raw materials and supplies	$2,347	$2,404
Finished goods	219	150
Total inventories	$2,566	$2,554

Property_and_Equipment_Details

Property and Equipment (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Property and equipment
Total property and equipment, at cost	$71,557	$62,224
Less accumulated depreciation	-49,854	-43,445
Total property and equipment, net	21,703	18,779
Depreciation expense	8,858	9,978	8,037
Cardiac monitoring devices, device parts and components
Property and equipment
Total property and equipment, at cost	47,190	37,273
Cardiac monitoring devices, device parts and components | Minimum
Property and equipment
Estimated Useful Life	3 years
Cardiac monitoring devices, device parts and components | Maximum
Property and equipment
Estimated Useful Life	5 years
Computers and purchased software
Property and equipment
Total property and equipment, at cost	12,614	13,302
Computers and purchased software | Minimum
Property and equipment
Estimated Useful Life	3 years
Computers and purchased software | Maximum
Property and equipment
Estimated Useful Life	5 years
Equipment, tools and molds
Property and equipment
Total property and equipment, at cost	5,543	5,384
Equipment, tools and molds | Minimum
Property and equipment
Estimated Useful Life	3 years
Equipment, tools and molds | Maximum
Property and equipment
Estimated Useful Life	5 years
Furniture and fixtures
Property and equipment
Estimated Useful Life	7 years
Total property and equipment, at cost	1,396	2,863
Leasehold improvements
Property and equipment
Total property and equipment, at cost	2,930	2,665
Capital leases
Property and equipment
Total property and equipment, at cost	$1,884	$737
Capital leases | Minimum
Property and equipment
Estimated Useful Life	3 years
Capital leases | Maximum
Property and equipment
Estimated Useful Life	7 years

Goodwill_and_Intangible_Assets2

Goodwill and Intangible Assets (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Changes in the carrying amounts of goodwill by segment
Balance at the beginning of the period	$16,469
Goodwill acquired during the year	13,127
Balance at the end of the period	29,596
Patient Services
Changes in the carrying amounts of goodwill by segment
Balance at the beginning of the period	1,577
Goodwill acquired during the year	12,912
Balance at the end of the period	14,489
Research Services
Changes in the carrying amounts of goodwill by segment
Balance at the beginning of the period	11,735
Goodwill acquired during the year	215
Balance at the end of the period	11,950
Product
Changes in the carrying amounts of goodwill by segment
Balance at the beginning of the period		3,157
Balance at the end of the period	$3,157	$3,157

Goodwill_and_Intangible_Assets3

Goodwill and Intangible Assets (Details 2) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Intangible assets
Total intangible assets, gross	$28,149	$9,860
Total accumulated amortization	-8,040	-4,348
Total intangible assets, net	22,720	7,312
Estimated amortization expenses
2015	4,628
2016	3,531
2017	2,828
2018	2,342
2019	1,768
Thereafter	5,012
Total intangibles assets, net	20,109
Amortization expense	3,692	2,340	1,341
Indefinite-lived trade name
Intangible assets
Indefinite-lived trade name	2,500	1,800
Customer relationships
Intangible assets
Total intangible assets, gross	10,700	2,100
Total accumulated amortization	-1,556	-722
Customer relationships | Minimum
Intangible assets
Estimated Useful Life	5 years
Customer relationships | Maximum
Intangible assets
Estimated Useful Life	15 years
Technology including internally developed software
Intangible assets
Total intangible assets, gross	12,649	4,000
Total accumulated amortization	-3,855	-1,902
Technology including internally developed software | Minimum
Intangible assets
Estimated Useful Life	3 years
Technology including internally developed software | Maximum
Intangible assets
Estimated Useful Life	5 years
Signed backlog
Intangible assets
Total intangible assets, gross	3,160	2,800
Total accumulated amortization	-1,984	-1,400
Signed backlog | Minimum
Intangible assets
Estimated Useful Life	1 year
Signed backlog | Maximum
Intangible assets
Estimated Useful Life	4 years
Unsigned backlog
Intangible assets
Estimated Useful Life	4 years
Total intangible assets, gross	600	600
Total accumulated amortization	-350	-200
Covenants not to compete
Intangible assets
Total intangible assets, gross	1,040	360
Total accumulated amortization	-295	-124
Covenants not to compete | Minimum
Intangible assets
Estimated Useful Life	5 years
Covenants not to compete | Maximum
Intangible assets
Estimated Useful Life	7 years
In-process internally developed software
Intangible assets
In-process internally developed software	$111

Accrued_Expenses_Details

Accrued Expenses (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Accrued Expenses
Accrued compensation	$5,296	$4,932
Accrued professional fees	8,289	1,922
Accrued purchases	977	311
Accrued restructuring costs	689	96
Other	3,209	929
Total	$18,460	$8,190

Integration_Restructuring_and_2

Integration, Restructuring and Other Charges (Details) (USD $)	3 Months Ended								12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Integration, Restructuring and Other Charges
Legal fees									$4,691	$5,516	$1,780
Severance and employee related costs									1,738	1,410	1,490
Professional fees									669	492	778
Expenses related to facility closure										564
Other charges											188
Total	$2,073	$1,045	$1,000	$2,980	$1,162	$3,077	$2,541	$1,202	$7,098	$7,982	$4,236

Shareholders_Equity_Details

Shareholders' Equity (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Shareholders' Equity
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares outstanding	26,693,248	25,812,754	25,189,340
Preferred stock, shares authorized	0	0
Preferred stock, shares outstanding	0	0
Stock-based compensation
Common stock available for grant (in shares)	2,262,168	1,761,840	1,442,434
2008 Option Plan
Stock-based compensation
Common stock available for grant (in shares)	1,834,017
Stock options
Number of Shares
Balance at the beginning of the period (in shares)	3,135,934	2,905,761	1,846,911
Granted (in shares)	582,012	729,439	1,387,560
Cancelled (in shares)	-310,303	-393,770	-326,458
Exercised (in shares)	-156,791	-105,496	-2,252
Balance at the end of the period (in shares)	3,250,852	3,135,934	2,905,761
Weighted Average Exercise Price
Balance at the beginning of the period (in dollars per share)	$5.83	$6.44	$10.11
Granted (in dollars per share)	$8.45	$3.24	$2.68
Cancelled (in dollars per share)	$6.55	$5.93	$11.34
Exercised (in dollars per share)	$3.37	$4.43	$1.61
Balance at the end of the period (in dollars per share)	$6.40	$5.83	$6.44
Stock options | 2008 Option Plan
Stock-based compensation
Increase in the number of options available to be granted as a percentage of total number of common shares outstanding	4.00%
Increase in the number of options available to be granted (in shares)	1,500,000
Stock options | 2008 Option Plan | Maximum
Stock-based compensation
Expiration period	10 years

Shareholders_Equity_Details_2

Shareholders' Equity (Details 2) (USD $)	12 Months Ended
	Dec. 31, 2014
$0.70 - $7.50
Summary of total outstanding stock options
Range of exercise prices, low end of range (in dollars per share)	$0.70
Range of exercise prices, high end of range (in dollars per share)	$7.50
Options Outstanding
Number Outstanding (in shares)	2,478,630
Weighted - Average Remaining Contractual Life	6 years 9 months 18 days
Weighted - Average Exercise Price (in dollars per share)	$4.08
Options Exercisable
Number Exercisable (in shares)	1,750,230
Weighted - Average Remaining Contractual Life	6 years 4 months 13 days
Weighted - Average Exercise Price (in dollars per share)	$4.43
$7.51 - $15.00
Summary of total outstanding stock options
Range of exercise prices, low end of range (in dollars per share)	$7.51
Range of exercise prices, high end of range (in dollars per share)	$15
Options Outstanding
Number Outstanding (in shares)	473,475
Weighted - Average Remaining Contractual Life	8 years 10 months 10 days
Weighted - Average Exercise Price (in dollars per share)	$8.94
Options Exercisable
Number Exercisable (in shares)	98,945
Weighted - Average Remaining Contractual Life	7 years 8 months 12 days
Weighted - Average Exercise Price (in dollars per share)	$8.93
$15.01 - $22.50
Summary of total outstanding stock options
Range of exercise prices, low end of range (in dollars per share)	$15.01
Range of exercise prices, high end of range (in dollars per share)	$22.50
Options Outstanding
Number Outstanding (in shares)	218,347
Weighted - Average Remaining Contractual Life	4 years 3 months 11 days
Weighted - Average Exercise Price (in dollars per share)	$18.42
Options Exercisable
Number Exercisable (in shares)	218,347
Weighted - Average Remaining Contractual Life	4 years 3 months 11 days
Weighted - Average Exercise Price (in dollars per share)	$18.42
$22.51 - $31.18
Summary of total outstanding stock options
Range of exercise prices, low end of range (in dollars per share)	$22.51
Range of exercise prices, high end of range (in dollars per share)	$31.18
Options Outstanding
Number Outstanding (in shares)	80,400
Weighted - Average Remaining Contractual Life	3 years 7 months 13 days
Weighted - Average Exercise Price (in dollars per share)	$30.17
Options Exercisable
Number Exercisable (in shares)	80,400
Weighted - Average Remaining Contractual Life	3 years 7 months 13 days
Weighted - Average Exercise Price (in dollars per share)	$30.17
$0.70 - $31.18
Summary of total outstanding stock options
Range of exercise prices, low end of range (in dollars per share)	$0.70
Range of exercise prices, high end of range (in dollars per share)	$31.18
Options Outstanding
Number Outstanding (in shares)	3,250,852
Weighted - Average Remaining Contractual Life	6 years 9 months 26 days
Weighted - Average Exercise Price (in dollars per share)	$6.40
Options Exercisable
Number Exercisable (in shares)	2,147,922
Weighted - Average Remaining Contractual Life	6 years 1 month 10 days
Weighted - Average Exercise Price (in dollars per share)	$7.02

Shareholders_Equity_Details_3

Shareholders' Equity (Details 3) (Stock options, USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Stock options
Stock-based compensation
Aggregate intrinsic value of options outstanding at year-end	$15,258	$11,183	$46
Aggregate intrinsic value of options exercisable at year-end	9,918	4,382	13
Aggregate intrinsic value of options exercised during the year	840	422	2
Total cash received from the exercise of stock options	$529	$467	$4

Shareholders_Equity_Details_4

Shareholders' Equity (Details 4) (Restricted stock units, USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Restricted stock units
Number of Shares
Balance at the beginning of the period (in shares)	857,656	763,342	622,080
Granted (in shares)	292,079	457,200	741,379
Forfeited (in shares)	-89,664	-82,813	-69,854
Vested (in shares)	-195,437	-280,073	-530,263
Balance at the end of the period (in shares)	864,634	857,656	763,342
Weighted Average Grant Date Fair Value
Balance at the beginning of the period (in dollars per shares)	$3.15	$3.54	$8.17
Granted (in dollars per share)	$8.48	$3.52	$2.82
Forfeited (in dollars per share)	$3.30	$3.07	$3.45
Vested (in dollars per share)	$6.27	$4.82	$8.03
Balance at the end of the period (in dollars per shares)	$3.68	$3.15	$3.54

Shareholders_Equity_Details_5

Shareholders' Equity (Details 5) (Restricted stock units, USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Stock-based compensation
RSUs Outstanding (in shares)	864,634	857,656	763,342	622,080
$2.16 - $6.75
Stock-based compensation
RSUs Outstanding (in shares)	632,201
$2.16 - $6.75 | Minimum
Stock-based compensation
Grant price (in dollars per share)	$2.16
$2.16 - $6.75 | Maximum
Stock-based compensation
Grant price (in dollars per share)	$6.75
$6.76 - $9.75
Stock-based compensation
RSUs Outstanding (in shares)	232,433
$6.76 - $9.75 | Minimum
Stock-based compensation
Grant price (in dollars per share)	$6.76
$6.76 - $9.75 | Maximum
Stock-based compensation
Grant price (in dollars per share)	$9.75
$2.16 - $9.75
Stock-based compensation
RSUs Outstanding (in shares)	864,634
$2.16 - $9.75 | Minimum
Stock-based compensation
Grant price (in dollars per share)	$2.16
$2.16 - $9.75 | Maximum
Stock-based compensation
Grant price (in dollars per share)	$9.75

Shareholders_Equity_Details_6

Shareholders' Equity (Details 6) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Weighted average assumptions used to estimate the fair value of the stock-based awards
Expected volatility (as a percent)	62.80%	60.30%	63.40%
Expected term	6 years 5 months 27 days	6 years 8 months 16 days	6 years 3 months 22 days
Weighted-average risk-free interest rate (as a percent)	1.85%	1.34%	1.15%
Expected dividends (as a percent)	0.00%	0.00%	0.00%
Weighted average fair value per option (in dollars per share)	$5	$1.90	$1.58
Weighted average fair value per RSU (in dollars per share)	$8.43	$3.52	$2.82
Stock options
Weighted average assumptions used to estimate the fair value of the stock-based awards
Future forfeiture rate (as a percent)	9.70%
Restricted stock units
Weighted average assumptions used to estimate the fair value of the stock-based awards
Future forfeiture rate (as a percent)	6.80%

Shareholders_Equity_Details_7

Shareholders' Equity (Details 7) (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Stock-based compensation
Stock based compensation	($4,037)	($3,303)	($3,747)
Denominator: Weighted average shares used in computing basic and diluted net loss per share	26,444,626	25,543,646	24,933,656
Impact of stock-based compensation expense (in dollars per share)	($0.15)	($0.13)	($0.15)
Stock options
Stock-based compensation
Total compensation cost of options granted but not yet vested	2,744	2,644	3,433
Weighted average remaining periods over which unrecognized amounts are expected to be recognized	2 years 8 months 5 days	2 years 1 month 21 days	2 years 4 months 2 days
Unvested awards (in shares)	1,102,930	1,491,574
Weighted-average grant-date fair value of unvested awards (in dollars per share)	$5.19	$3.45
Restricted stock units
Stock-based compensation
Stock-based compensation expense related to nonvested awards	$1,979	$1,795	$1,892
Weighted average remaining periods over which unrecognized amounts are expected to be recognized	1 year 6 months	1 year 3 months 22 days	1 year 5 months 19 days
Unvested awards (in shares)	864,634	857,656
Weighted-average grant-date fair value of unvested awards (in dollars per share)	$4.23	$3.15

Shareholders_Equity_Details_8

Shareholders' Equity (Details 8) (USD $)	1 Months Ended	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Jan. 31, 2014	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Stock-based compensation
Remaining shares available under Plan		2,262,168	1,761,840	1,442,434
Expenses incurred		$4,037	$3,303	$3,747
Employee Stock Purchase Plan
Stock-based compensation
Maximum percentage of compensation that employees may contribute through payroll deductions		15.00%
Maximum amount that employees may contribute through payroll deductions		21
Percentage of the fair market price on the first day of the offering period or the market price as on the day of purchase		85.00%
Common stock purchased (in shares)		346,245
Proceeds from the issuance of shares of common stock (in dollars)		871
Increase in number of shares available for grant	258,240
Remaining shares available under Plan		428,151
Expenses incurred		$408	$211	$182

Shareholders_Equity_Details_9

Shareholders' Equity (Details 9) (Stock options, USD $)	0 Months Ended	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 01, 2009	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Stock options
Option Acceleration
Threshold percentage for determining deeply out-of-the-money options	30.00%
Number of previously unvested shares, which became fully vested as a result of option acceleration	309,000
Expense associated with the accelerated options		$0	$137	$578

Income_Taxes_Details

Income Taxes (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Deferred tax assets:
Net operating loss carryforwards	$38,540	$37,335
Research & development and AMT credit carryforwards	5,314	4,687
Stock option grants	7,410	6,533
Allowance for doubtful accounts	4,532	3,101
Other, net	1,518	1,928
Total deferred tax assets	57,314	53,584
Less valuation allowance	-52,998	-50,979
Net deferred tax assets	4,316	2,605
Deferred tax liabilities:
Property, plant and equipment	-360	-345
Identified intangible assets	-3,756	-2,089
Indefinite lived intangible assets	-987	-730
Prepaid insurance	-200	-171
Total deferred tax liabilities	-5,303	-3,335
Net deferred tax liability	-987	-730
Reconciliation between expected income taxes computed at the federal rate and the provision (benefit) for income taxes
Federal rate of income tax (as a percent)	35.00%	35.00%	35.00%
Income tax benefit at statutory rate	-4,237	-2,486	-4,587
State income tax, net of federal benefit	4	716	-211
Stock-based compensation	43	203	397
Other	-258	182	200
Increase in valuation allowance	2,135	1,600	3,296
Income tax provision (benefit)	-2,313	215	-905
Net Operating Loss Carryforwards
Minimum percentage of increase in ownership of stockholders for ownership change	50.00%
Period over which a minimum 50 percent of increase in ownership is required for ownership change	3 years
Period of recognition of built-in gains in assets held at the time of ownership change	5 years
Current:
Federal		24
State	186	138
Total current provision for income taxes	186	162
Deferred:
Federal	-2,355
State	-144	53
Total deferred provision (benefit) for income taxes	-2,499	53	-1,033
Income tax provision (benefit)	-2,313	215	-905
Tax reserve recorded for tax contingencies	0	0
Federal
Net Operating Loss Carryforwards
Net operating loss carryforwards	100,977
State
Net Operating Loss Carryforwards
Net operating loss carryforwards	47,776
Research and Development
Net Operating Loss Carryforwards
Tax credit carryforward	$4,906

Commitments_and_Contingencies_1

Commitments and Contingencies (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Commitments and Contingencies
Rent expense	$3,721	$3,622	$2,946
Future minimum lease payments under non-cancelable operating leases
2015	3,277
2016	2,941
2017	2,836
2018	2,770
2019	1,357
Thereafter	1,458
Total	14,639
Future minimum lease payments under capital leases
2015	480
2016	287
2017	101
Total	$868

Credit_Agreement_Details

Credit Agreement (Details) (USD $)	1 Months Ended	0 Months Ended	12 Months Ended	1 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 30, 2014	Dec. 31, 2014	Apr. 30, 2014	Feb. 28, 2014	Aug. 31, 2012
Credit Agreement
Loss on extinguishment of debt	$372
Mednet
Credit Agreement
Amount of assumed debt associated with acquisition					8,563
GE Capital
Credit Agreement
Percentage of capital stock of Cardiocore Lab Ltd. and BioTelemetry Belgium pledged to secure loan		65.00%
GE Capital | LIBOR
Credit Agreement
Debt instrument, basis spread on variable rate (as a percent)		4.00%
LIBOR floor (as a percent)		1.00%
GE Capital | Term Loan
Credit Agreement
Maximum borrowing capacity		25,000
Additional uncommitted borrowing capacity		10,000
Loan balance net of original issue discount		24,008
Original issue discount		992
GE Capital | Term Loan | April 2015 to December 2017
Credit Agreement
Principal amount of quarterly installment payments		312
GE Capital | Term Loan | January 2018 to September 2019
Credit Agreement
Principal amount of quarterly installment payments		625
GE Capital | Term Loan | October 2019 to December 2019
Credit Agreement
Remaining principal amount to be paid in full		16,563
GE Capital | Revolving Loan
Credit Agreement
Maximum borrowing capacity		15,000
MidCap Financial, LLC
Credit Agreement
Maximum borrowing capacity						15,000
Potential maximum loan commitment						30,000
Loan termination fee (as a percent)			1.00%
Extinguishment of debt	8,000
MidCap Financial, LLC | BMS
Credit Agreement
Amount withdrawn for acquisition				8,000
The Bancorp Bank
Credit Agreement
Aggregate amount of agreement with The Bancorp Bank					9,830
Extinguishment of debt	$9,411

Employee_Benefit_Plan_Details

Employee Benefit Plan (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Employee Benefit Plan
Employer's matching contribution as a percent of of the first 3% of employees' salary contributed	100.00%
Percentage of employees' salary contributed matched 100% by employer	3.00%
Employer's matching contribution as a percent of of the next 2% of employees' salary contributed	50.00%
Percentage of employees' salary contributed matched 50% by employer	2.00%
Employer's contribution	$1,483	$0	$0

Segment_Information_Details

Segment Information (Details) (USD $)	3 Months Ended								12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
									segment
Segment Information
Number of operating segments									3
Segment information
Revenues	$43,653	$43,113	$42,650	$37,162	$33,105	$31,874	$32,104	$32,418	$166,578	$129,501	$111,494
Income (loss) before income taxes									-12,106	-7,104	-13,107
Depreciation and amortization									12,550	12,318
Capital expenditures									12,781	8,169
Patient Services
Segment information
Revenues									133,178	100,386
Capital expenditures									11,488	5,796
Research Services
Segment information
Revenues									19,744	20,329
Capital expenditures									1,077	2,242
Product
Segment information
Revenues									13,656	8,786
Capital expenditures									216	131
Operating segments | Patient Services
Segment information
Income (loss) before income taxes									27,792	27,298
Depreciation and amortization									8,157	4,253
Operating segments | Research Services
Segment information
Income (loss) before income taxes									-701	798
Depreciation and amortization									3,710	4,057
Operating segments | Product
Segment information
Revenues									7,789	6,191
Income (loss) before income taxes									6,681	5,307
Depreciation and amortization									502	551
Corporate and Other
Segment information
Revenues									-7,789	-6,191
Income (loss) before income taxes									-45,878	-40,507
Depreciation and amortization									$181	$3,457

Legal_Proceedings_Details

Legal Proceedings (Details) (USD $)	0 Months Ended
In Thousands, except Share data, unless otherwise specified	Jan. 31, 2014	8-May-12
		patent
CardioNet | Mednet
Legal proceedings
Cash consideration paid under purchase agreement	$5,500
Value of common stock issued for acquisition	705
CardioNet v. ScottCare Litigation
Legal proceedings
Number of patents allegedly infringed		5
Litigation settled | CardioNet v. Mednet Litigation
Legal proceedings
Number of patents infringed by the defendants	5
Litigation settled | CardioNet v. Mednet Litigation | Mednet
Legal proceedings
Cash consideration paid under purchase agreement	5,500
Shares of common stock issued under definitive stock purchase agreement	96,649
Assumed outstanding secured debt, including interest under definitive stock purchase agreement	$9,720

Legal_Proceedings_Details_2

Legal Proceedings (Details 2) (CardioNet, Inc. and Braemar Manufacturing, LLC, USD $)	Dec. 31, 2014
In Thousands, unless otherwise specified
CardioNet, Inc. and Braemar Manufacturing, LLC
Legal proceedings
Accrual of contingent liabilities	$0

Civil_Investigative_Demand_Det

Civil Investigative Demand (Details) (Civil Investigative Demand, USD $)	6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014
Civil Investigative Demand
Civil Investigative Demand
Amount of non-operating charge	$6,400

Quarterly_Financial_Data_Unaud2

Quarterly Financial Data (Unaudited) (Details) (USD $)	3 Months Ended								12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Quarterly Financial Data (Unaudited)
Total revenues	$43,653	$43,113	$42,650	$37,162	$33,105	$31,874	$32,104	$32,418	$166,578	$129,501	$111,494
Gross profit	24,529	23,678	23,613	21,644	20,795	19,234	19,496	19,545	93,464	79,070	65,901
Integration, restructuring and other charges	2,073	1,045	1,000	2,980	1,162	3,077	2,541	1,202	7,098	7,982	4,236
(Loss) income from operations	-702	486	-401	-3,696	226	-2,835	-2,238	-2,034	-4,313	-6,881	-13,159
Net loss	($1,654)	($29)	($3,988)	($4,122)	$23	($2,956)	($2,299)	($2,087)	($9,793)	($7,319)	($12,202)
Basic and diluted net loss per share	($0.06)	$0	($0.15)	($0.16)	$0	($0.12)	($0.09)	($0.08)	($0.37)	($0.29)	($0.49)

Schedule_IIAllowance_for_Doubt1

Schedule II-Allowance for Doubtful Accounts (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Allowance for Doubtful Accounts
Beginning Balance	$7,640	$7,617	$9,889
Additions Charged To Expense	9,347	7,787	11,912
Deductions From Reserve	-6,325	-7,763	-14,184
Ending Balance	$10,662	$7,640	$7,617